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ABSTRACT 
Diseases caused by the Lancefield group A streptococcus, Streptococcus pyogenes, are 
amongst the most challenging to clinicians and public health specialists alike.  Although 
severe infections caused by S. pyogenes are relatively uncommon, affecting around 3 
per 100,000 of the population per annum in developed countries, the case fatality is high 
relative to many other infections.  Despite a long scientific tradition of studying their 
occurrence and characteristics, many aspects of their epidemiology remain poorly 
understood, and potential control measures undefined.   
 
Epidemiological studies can play an important role in identifying host, pathogen and 
environmental factors associated with risk of disease, manifestation of particular 
syndromes or poor survival.  This can be of value in targeting prevention activities, as 
well directing further basic research, potentially paving the way for the identification of 
novel therapeutic targets.  The formation of a European network, Strep-EURO, provided 
an opportunity to explore epidemiological patterns across Europe.  
 
Funded by the Fifth Framework Programme of the European Commission’s Directorate-
General for Research (QLK2.CT.2002.01398), the Strep-EURO network was launched 
in September 2002.  Twelve participants across eleven countries took part, led by the 
University of Lund in Sweden.  Cases were defined as patients with S. pyogenes 
isolated from a normally sterile site, or non-sterile site in combination with clinical signs 
of streptococcal toxic shock syndrome (STSS).  All participating countries undertook 
prospective enhanced surveillance between 1st January 2003 and 31st December 2004 
to identify cases diagnosed during this period.   
 
A standardised surveillance dataset was defined, comprising demographic, clinical and 
risk factor information collected through a questionnaire.  Isolates were collected by the 
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national reference laboratories and characterised according to their M protein using 
conventional serological and emm gene typing.  
 
Descriptive statistics and multivariable analyses were undertaken to compare 
characteristics of cases between countries and identify factors associated with increased 
risk of death or development of STSS.  Crude and age-adjusted rates of infection were 
calculated for each country where a catchment population could be defined. 
 
The project succeeded in establishing the first European surveillance network for severe 
S. pyogenes infections, with 5522 cases identified over the two years.  Analysis of data 
gathered in the eleven countries yielded important new information on the epidemiology 
of severe S. pyogenes infections in Europe during the 2000s.  Comprehensive 
epidemiological data on these infections were obtained for the first time from France, 
Greece and Romania.  Incidence estimates identified a general north-south gradient, 
from high to low.  Remarkably similar age-standardised rates were observed among the 
three Nordic participants, between 2.2 and 2.3 per 100,000 population.  Rates in the UK 
were higher still, 2.9/100,000, elevated by an upsurge in drug injectors.  Rates from 
these northern countries were reasonably close to those observed in the USA and 
Australia during this period.  In contrast, rates of reports in the more central and 
southern countries (Czech Republic, Romania, Cyprus and Italy) were substantially 
lower, 0.3 to 1.5 per 100,000 population, a likely reflection of poorer uptake of 
microbiological diagnostic methods within these countries.   
 
Analysis of project data brought some new insights into risk factors for severe S. 
pyogenes infection, especially the importance of injecting drug users in the UK, with 
infections in this group fundamentally reshaping the epidemiology of these infections 
during this period.  Several novel findings arose through this work, including the high 
degree of congruence in seasonal patterns between countries and the seasonal 
changes in case fatality rates.  Elderly patients, those with compromised immune 
systems, those who developed STSS and those infected with an emm/M78, emm/M5, 
emm/M3 or emm/M1 were found to be most likely to die as a result of their infection, 
whereas those diagnosed with cellulitis, septic arthritis, puerperal sepsis or with non-
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focal infection were associated with low risk of death, as were infections occurring during 
October.  Analysis of augmented data from the UK found use of NSAIDs to be 
significantly associated with development of STSS, adding further fuel to the debate 
surrounding the role of NSAIDs in the development of severe disease. 
 
As a largely community-acquired infection, occurring sporadically and diffusely 
throughout the population, opportunities for control of severe infections caused by S. 
pyogenes remain limited, primarily involving contact chemoprophylaxis where clusters 
arise.  Analysis of UK Strep-EURO data were used to quantify the risk to household 
contacts of cases, forming the basis of national guidance on the management of 
infection.  Vaccines currently under development could offer a more effective control 
programme in future.   
 
Surveillance of invasive infections caused by S. pyogenes is of considerable public 
health importance as a means of identifying long and short-term trends in incidence, 
allowing the need for, or impact of, public health measures to be evaluated.  As a 
dynamic pathogen co-existing among a dynamic population, new opportunities for 
exploitation of its human host are likely to arise periodically, and as such continued 
monitoring remains essential.  
 
Keywords: Streptococcus pyogenes; Fatal Outcome; Shock, septic; Seasons; 
Bacteraemia; Streptococcal vaccines; Communicable disease control; Population 
Surveillance; Epidemiology; Europe, UK. 
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TIIVISTELMÄ
 
 
Lancefield-ryhmän A streptokokin eli Streptococcus pyogenes-bakteerin aiheuttamat 
taudit ovat erittäin haasteellisia kliinikoille sekä kansanterveyden asiantuntijoille.  Vaikka 
S. pyogenesin aiheuttamia vakavia infektioita esiintyy kehittyneissä maissa 
väestöpohjaisesti vain kolmella 100 000:sta vuosittain, on tapauskuolleisuus suuri 
verrattuna moniin muihin infektiotauteihin.  Siitä huolimatta, että näiden infektioiden 
ominaisuuksia ja esiintymistä koskevalla tutkimuksella on pitkät perinteet, on niiden 
epidemiologia vielä useilta osin huonosti tunnettua ja mahdolliset torjuntakeinot 
määrittelemättä.  
 
Epidemiologisilla tutkimuksilla voi olla merkittävä rooli tautiriskiin, tiettyihin oireisiin tai 
huonoon selviytymiseen liittyvien isäntään, taudinaiheuttajaan ja ympäristötekijöihin 
liittyvien tekijöiden tunnistamisessa.  Tämä voi osoittautua hyödylliseksi 
ehkäisytoimenpiteitä ja jatkotutkimuksia suunnitellessa, sekä toimia uraauurtavasti 
uusien hoidon kohteiden tunnistamisessa.  Eurooppalaisen Strep-EURO- verkoston 
perustaminen mahdollisti epidemiologisten tekijöiden tutkimuksen ympäri Eurooppaa.  
 
Euroopan komission tutkimusdirektoraatin (QLK2.CT.2002.01398) viidennen 
puiteohjelman rahoittama Strep-EURO -verkosto perustettiin syyskuussa 2002.   
Hankkeeseen osallistui kaksitoista osanottajaa yhdestätoista maasta ruotsalaisen 
Lundin yliopiston johdolla. Tapauksiksi määriteltiin potilaat, joilta oli viljelty S. pyogenes 
joko normaalisti steriilistä tai epästeriilistä kohteesta yhdistettynä toksisen shokin 
taudinkuvaan (STSS). Prospektiivisen tehoseurantatutkimuksen avulla etsittiin kaikista 
osallistujamaista 1. tammikuuta 2003 ja 31. joulukuuta 2004 välisenä aikana 
diagnostisoituja potilastapauksia. 
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Luotiin standardisoidu seurantatietokanta, joka sisälsi kyselylomakkeen avulla kerättyjä 
demografisia, kliinisiä ja riskitekijätietoja. Kansalliset asiantuntijalaboratoriot keräsivät 
bakteerilöydökset, ja tutkivat niiden M proteiineja perinteistä serologista ja emm -
geenityypitystä hyödyntämällä. 
 
Deskriktiivinen tilasto- ja monimuuttuja-analyysi suoritettiin eri maiden välillä 
tautitapauksiin liittyvien ominaisuuksien sekä suurentuneeseen kuolemanriskiin tai 
STSS:n kehittymiseen liittyvien riskitekijöiden tunnistamiseksi. Infektioiden 
esiintymisluvut laskettiin sekä suoraan että ikäryhmiin mukautettuna kullekin maalle, 
jonka kohdeväestö oli määriteltävissä. 
 
Tunnistamalla 5522 tapausta kahden vuoden aikana, hanke onnistui luomaan 
ensimmäisen eurooppalaisen vakavien S. pyogenes infektioiden seurantaverkoston.  
Yhdessätoista maasta kerättyä materiaalia analysoimalla saatiin uutta, tärkeää tietoa 
vakavien S.pyogenes infektioiden epidemiologiasta Euroopassa 2000-luvulla.  Kattavaa 
epidemiologista tietoa näistä infektioista oli saatavilla ensimmäistä kertaa Ranskasta, 
Kreikasta ja Romaniasta.  Tapausten esiintymistiheys viittasi korkeasta alhaiseen 
kulkevaan pohjois-etelä gradienttiin.  Kolmen pohjoismaalaisen osallistujan välillä oli 
nähtävissä huomattavan yhdenmukaiset ikävakioidut arvot, noin 2,2 -2,3 tapausta 
100 000 asukasta kohti.  Ruiskuhuumeita käyttävien äkillisesti nousseesta lukumäärästä 
johtuen olivat kyseiset luvut Iso-Britaniassa vielä korkeampia, noin 2,9/100 000.  Näistä 
Pohjois-Euroopan maista saadut luvut vastasivat suunnilleen USA:sta ja Australiasta 
samalla aikavälillä saatuja arvoja.  Euroopan keski- ja eteläosan maissa (Tsekin 
tasavalta, Romania, Kypros ja Italia) havaittiin sen sijaan huomattavasti vähemmän 
tapauksia ja kyseiset luvut vaihtelivat 0,3:n ja 1,5:n tapauksen välillä 100 000 asukasta 
kohti.  Tämän voidaan mitä todennäköisimmin katsoa heijastuvan mikrobiologisten 
diagnostisten menetelmien vähemmästä käytöstä kyseisissä maissa.  
 
Projektitulosten analysointi toi joitakin uusia näkökulmia vakavien S. pyogenes tautien 
riskitekijöistä.  Etenkin Iso-Britanniassa ruiskuhuumeiden käyttö ja näiden potilaiden 
infektiot muokkasivat merkittävästi tautiepidemiologiaa tänä ajanjaksona.  Tutkimus tuotti 
paljon uusia tuloksia, kuten vuodenaikavaihtelun samankaltaisuuden kaikissa maissa, ja 
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vuodenajan vaikutuksen tapauskuolleisuuteen. Iäkkäät ja puolustusrajoitteiset potilaat 
sekä henkilöt, joille oli kehittynyt STSS tai joilla oli emm/M78, emm/M5, emm/M3 tai 
emm/M1 tauti, kuolivat todennäköisimmin infektion seurauksena, kun taas selluliittia, 
septistä artriittia, puerperaalista sepsistä tai yleisinfektiota (ei elinfokusta) sairastavien 
potilaiden keskuudessa kuolemanriski oli alhainen.  Kuolleisuus oli alhaisempaa myös, 
jos infektio esiintyi lokakuussa.  Iso-Britannian laajennetun tietokeräysmateriaalin 
analyysissa NSAID lääkkeiden käyttö assosioitui tilastollisesti merkitsevästi STSS:n 
kehittymiseen.  Tämä löydös saattaa osaltaan kiihdyttää keskustelua, jota käydään 
NSAID lääkkeiden roolista vakavan taudin kehittymiseen. 
 
Koska vakavat S.pyogenes infektiot ovat pitkälti avohoitoperäisiä, ja ajallisesti ja 
maantieteellisesti harvakseltaan esiintyviä tauteja, ovat torjuntakeinot vähäiset.  Ne 
rajoittuvat lähinnä lähikontaktien lääkeprofylaksiaan, jos todetaan tautirypäitä.  Iso-
Britannian Strep-EURO tuloksia käytettiin arvioimaan samassa taloudessa asuvien 
henkilöiden tautiriskiä; tämä loi pohjaa kansallisen hoito-ohjeen luonnille.  Kehitteillä 
olevat rokotteet voisivat tulevaisuudessa tarjota tehokkaamman torjuntaohjelman.  
 
Vakavien S. pyogenes infektioiden seuranta on kansanterveydellisesti tärkeää 
nimenomaan pitkän ja lyhyen ajanjakson esiintyvyydessä tapahtuvien muutosten 
tunnistamiseksi, sekä kansanterveydellisten toimenpiteiden tarpeen ja vaikutusten 
arvioimiseksi.  S. pyogenes, joka on muuntautumiskykyinen taudinaiheuttaja, osaa 
väestössä ja isännässä tapahtuvien muutosten myötä etsiä aika ajoin uusia 
taudinaiheuttamismuotoja.  Tämän takia jatkuva seuranta on tärkeää.    
 
Avainsanat: Streptococcus pyogenes, kuolema; shokki; septinen; kausi/vuodenaika; 
bakteremia; streptokokkirokotteet; tartuntatautien torjunta; väestön seuranta; 
epidemiologia; Eurooppa; Iso-Britannia. 
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ABBREVIATIONS 
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1. INTRODUCTION  
 
Diseases caused by the Lancefield group A streptococcus, Streptococcus pyogenes, are 
among the most varied in terms of clinical spectra and severity, ranging from the 
ubiquitous pharyngitis to rarer life-threatening presentations such as necrotizing fasciitis.  
Although severe infections caused by S. pyogenes are relatively uncommon, affecting 
around 3 per 100,000 of the population per annum in developed countries[1;2], the case 
fatality is high relative to many other infections, around 7-23%[2-8].  The rapidity with 
which patients can deteriorate bestows further notoriety to this pathogen[9-11], inducing 
disquiet among frontline medical staff faced with a differential diagnosis, and fear 
amongst the public at large.  Although attributable mortality is higher among the elderly 
and those with impaired immune systems, deaths among the young and previously 
healthy are not uncommon[11-13]. 
 
Invasive S. pyogenes infections have attracted increasing levels of attention since the 
late 1980s when reports from the USA, Canada, Norway, Sweden and Denmark warned 
of a possible re-emergence of severe clinical manifestations of S. pyogenes, and non-
suppurative sequelae such as rheumatic fever[9;11;14-19].  Serotype M1, and to a 
lesser extent M3, were generally implicated in these rises[10;16;20;21]. 
 
During the early 1980s reports emerged from the then Czechoslovakia and the USA 
describing a hitherto unrecognized complication of S. pyogenes infection, termed the 
‘streptococcal toxic shock-like syndrome’[6;12;22;23].  A review of these reports by a 
CDC working group led to the establishment of a case definition for streptococcal toxic 
shock-like syndrome (STSS)[24].  The diverse spectrum of invasive diseases recognised 
as being caused by Streptococcus pyogenes included puerperal sepsis, necrotizing 
fasciitis, septic arthritis, pneumonia, STSS and non-focal bacteraemia. 
 
One of the most defining events for severe S. pyogenes disease surveillance activity 
occurred in 1994 when a cluster of necrotizing fasciitis cases was detected in 
Gloucestershire, in the South West of England[25].  This event acted as an important 
catalyst for a host of activity within and outside the UK.  Enhanced surveillance for 
severe S. pyogenes disease was immediately implemented in the UK[26], with two other 
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European countries following suit[27;28].  This response resulted in a small number of 
countries obtaining for the first time measures of disease-specific incidence, risk factors 
and outcome.   
 
The impetus generated during the mid-1990s led to the establishment of an ad hoc 
WHO working group on Streptococcus pyogenes, comprised of representatives from 
streptococcal reference centres in Canada, Czech Republic, Italy, New Zealand, UK and 
USA.  The main recommendation of the ensuing WHO consultations was to support 
member countries in initiating comprehensive public health programmes for the control 
of severe S. pyogenes infections.  The key priorities that emerged from the pivotal 1998 
consultation included the urgent need to develop a mechanism to strengthen 
microbiological capacity and provide sustained support to an international network of 
laboratories, the need to evaluate the tools available for surveillance, and the need to 
embed streptococcal infections within national public health priorities[29].  However, no 
definitive network across Europe was formed, and collaborations between European 
countries were undertaken, if at all, on a largely informal basis.  A European network 
was not established until 2002[30].   
 
Despite the importance of these infections and the long scientific tradition of studying 
their occurrence and characteristics, many aspects of their natural history remain poorly 
understood, and potential control measures often undefined.  Epidemiological studies 
can identify a range of host, pathogen and environmental factors associated with 
particular disease manifestations or with poor survival, which can in turn help direct 
further research at a cellular level, potentially paving the way for identification of novel 
therapeutic or preventative targets.  Collecting an array of patient and microbiological 
data on at a sufficiently large and representative number of patients can, however, 
present a logistical and financial challenge.  The formation of a European network, 
Strep-EURO, provided an opportunity to rise to this challenge[31].  
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2. REVIEW OF THE LITERATURE  
2.1. Streptococcus pyogenes as a human pathogen 
2.1.1. Discovery of Streptococcus pyogenes 
Like other members of the family Streptococcacae, streptococci are Gram-positive 
facultative anaerobic organisms which occur in chains or in pairs[32].  The name 
Streptococcus was proposed by Theodor Billroth in 1874, who identified these 
organisms from patients with erysipelas and wound infections[33;34].  The name was 
coined in recognition of the characteristic chain formation of the genus, from the Greek 
streptos for chain or twisted, and kokhos meaning berry or seed, referring to the 
globular-shaped particles[35].  The individual streptococcal species then became named 
after the diseases they caused or sites of infection[35], with Streptococcus pyogenes 
coined by Friedrich Julius Rosenbach in 1884[34;36].  
 
Streptococci were first classified at the turn of the 20th Century according to their 
differential capacity to induce haemolysis on blood agar[35].  Pioneering work by 
Rebecca Lancefield during the 1930s proposed a serological classification scheme 
based on group-specific polysaccharides[35;37].  She further subdivided group A 
streptococci according to the M protein found on the cell wall, an important virulence 
factor against which protective antibodies are formed[34].  Research undertaken during 
the 1920s and 1930s also identified toxins (streptococcal pyrogenic exotoxins) produced 
by streptococci as having an important role in the pathogenesis of scarlet fever[35]. 
 
2.1.2. Carriage and transmission of S. pyogenes 
Streptococcus pyogenes is commonly carried in the oropharynx and on intact skin of 
humans.  The genital tract and perianal area are also sites of carriage.  Carriage rates 
vary according to geographical location, climatic factors, season and age[34].  Estimates 
of pharyngeal carriage range from 12-23% in school-aged children [38;39].  S. pyogenes 
can also contaminate the environment immediately around carriers and those with 
disease[40].  Different M-types are known to favour mucosal versus cutaneous sites, the 
latter constituting the higher-numbered types in reflection of their more recent 
identification[34].  There is some evidence that some serotypes have more pathogenic 
potential than others[41]. 
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Transmission of S. pyogenes is usually through direct contact with droplets of saliva or 
nasal secretions from carriers or persons with clinical infection, or through skin contact, 
especially contact with infected lesions.  Seminal work carried out at the Warren Air 
Force base in Wyoming (USA) found transmission rates to be higher in symptomatic 
than asymptomatic individuals, from individuals carrying the organism in their nose than 
throat, and from those heavily colonised[42].  Transmission rates have also been found 
to be increased by crowding[34;42].  The length of incubation is usually fairly short, 
usually 1-3 days[43].  The period of communicability is typically 10-21 days in untreated 
individuals with uncomplicated infection.  This is significantly reduced once antibiotic 
treatment has commenced[34;43], with less than 20% of children in one study found to 
have a positive throat swab 24 hours after commencement of treatment[44]. 
 
2.1.3. Diseases caused by S. pyogenes 
A wide range of clinical infections are recognised as being caused by Streptococcus 
pyogenes, including respiratory, cutaneous, soft tissue and systemic infections.  
Suppurative presentations commonly associated with this organism are listed in Table 1, 
with most being potentially caused by a range of different pathogens[34].  The two most 
important non-suppurative presentations are rheumatic fever and glomerulonephritis. 
 
Table 1  Suppurative infections caused by S. pyogenes 
Non-focal bacteraemia 
Skin and soft tissue infections 
Cellulitis Impetigo 
Erysipelas Necrotizing fasciitis 
Carditis  
Meningitis  
Upper and lower respiratory tract infections 
Epiglottitis Pharyngitis 
Empyema Scarlet fever 
Mastoiditis Tonsillitis 
Otitis Pneumonia 
Bone and joint infections 
Abdominal infections  
Peritonitis Appendicitis 
Pelvic and obstetric infections 
Puerperal sepsis Vaginitis 
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Puerperal sepsis or ‘childbed fever’ has represented one the most important of these 
disease manifestations in developed countries during the past three centuries.  The 
introduction of ‘lying-in’ hospitals in the 17th and 18th Centuries across Europe and the 
subsequent shift from home birth to hospital delivery provided ideal conditions for the 
spread of infection[45-47].  High rates of maternal death began to be reported across 
Europe, with a staggering 1 in 5 maternities in one hospital in Stockholm resulting in 
death[48].  Seminal findings by Semmelweis in the 1840s demonstrated that the disease 
was spread through contagious particles carried on hands and overalls of attending 
clinicians[49].  It took a further 30 years however before this became accepted and 
infection control measures instigated following the identification of streptococci in clinical 
specimens by Billroth and Pasteur during the 1870s[48;50].  
 
Development of a mechanism to identify and classify Streptococcus pyogenes during the 
early part of the 20th Century paved the way for the epidemiological study of important 
disease manifestations: scarlet fever, acute rheumatic fever and puerperal sepsis.  
Incidence and severity of these diseases fell dramatically over the past century.  
Recognition of the causative organisms and factors facilitating transmission are likely to 
have influenced the changing incidence of infection, along with development of 
antibacterial drugs for use in treatment and prophylaxis during the 1940s[35].  However, 
incidence of these infections appears to have been falling prior to these developments 
(Figure 1, HPA), suggestive that other host or pathogen factors may have been 
important in reducing transmission or infection, for example improved living conditions 
and general health, or a possible diminution in strain virulence. 
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Figure 1  Notifications of scarlet fever in England and Wales, 1912-2007 
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After a century of declining incidence of rheumatic fever, reports began to emerge from 
the USA suggesting a resurgence of disease in military and civilian populations during 
1980s[51].  Whilst a resurgence in rheumatic fever in other countries was not generally 
documented, widespread increases in incidence of invasive disease began to be 
reported from the 1980s onwards (see 2.4. The burden of severe S. pyogenes 
infection at the turn of the millennium). 
 
2.2. Measuring and monitoring the incidence of severe S. 
pyogenes infection 
Our understanding of the epidemiology of severe diseases caused by S. pyogenes is 
relatively poor compared to many other infectious diseases.  Many countries with 
established infectious disease surveillance programmes have undertaken relatively little 
surveillance of diseases caused by S. pyogenes and other streptococci.  However, many 
are now expanding or modifying their surveillance programmes to capture information on 
diagnoses of severe S. pyogenes infection, not least in light of recent worrying trends in 
incidence. 
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Two distinct approaches are commonly used to obtain data of value in understanding 
and characterising the spread of infections in a population.  The most common, 
pragmatic and economical approach is to find an existing source of information on the 
diseases of interest, such as point of contact with healthcare services, and establish a 
mechanism to capture relevant information from this source.  In contrast to this 
opportunistic approach is the establishment of a customised system to capture data not 
available through existing sources.  The advantage of the first approach is that it clearly 
requires less resource than the second, either from central co-ordinators or from local 
data providers.  This approach is limited, however, to diseases that lead patients to seek 
contact with healthcare services and to information routinely captured. 
 
To fully understand the epidemiology of diseases caused by S. pyogenes, an 
understanding of transmission dynamics are needed, in terms of how this organism 
spreads, host and strain characteristics of importance to onward transmission and 
disease severity and inter- and intra-species competition for ecological niches.  A 
comprehensive investigation following a very large healthy cohort for a substantial period 
of time would have to be undertaken to explore these dynamics, given the rarity of some 
of the severe presentations one would be trying to capture.  Although this would reveal a 
host of new information on transmission and incidence, an important first step towards 
identifying effective prevention strategies, clearly this would be prohibitively expensive.  
As such, studies have tended to focus on specific elements of disease transmission and 
incidence. 
 
 
2.2.1. Statutory requirements for the notification of S. pyogenes 
diseases 
Very few countries within Europe list severe S. pyogenes infection among their notifiable 
diseases.  In Norway cases of invasive S. pyogenes infection have been notifiable since 
1975, and all severe infections (including isolates from non-sterile sites, when 
accompanied by severe clinical presentation) since 1995[52]. Finland similarly made S. 
pyogenes bacteraemia notifiable in 1995, as have Ireland in 2003 and Sweden in 2004 
[53-55].  With the exception of these countries, surveillance activities have been 
predominantly reliant on voluntary reporting systems.  There is no current requirement 
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for national public health institutes to report cases of severe S. pyogenes disease to 
ECDC[56;57]. 
 
2.2.2. Surveillance methodology 
An international network encompassing countries bordering the Arctic (International 
Circumpolar Surveillance) has been in operation for a number of years, although capture 
of data on invasive S. pyogenes infections has been limited to the USA, Canada and 
Greenland[58].  In the absence of a dedicated Europe-wide surveillance network, 
different European countries have been undertaking surveillance of S. pyogenes 
infections according to their own criteria.  Common methodological approaches have 
been adopted between countries, allowing some degree of comparability of results.  
National or multi-site surveillance activity results identified from the WHO European 
Region are given in Table 2 (based on Lamagni et al[31], with additional data) and from 
other WHO regions combined in Table 3.  Most operate through the capture of routine 
local microbiological diagnoses into a central data bank.  The quality of data available 
through such systems has been variable, both in terms of the breadth of information 
collected and completeness of reporting.  Many such systems do not routinely capture 
clinical information, which is a particular shortfall for S. pyogenes infection given the 
plethora of associated conditions and their differing risk factors.   
 
As many industrialised countries have a recognised national reference centre for 
microbiological identification and typing of streptococci, surveillance activities have 
commonly utilised isolate submission for surveillance purposes.  This provides 
information on microbiological characteristics of strains circulating within these countries, 
such as serotype (based on T and M proteins), sequence typing of the emm gene 
(emmST) and antibiotic susceptibility.  A potential drawback can be referral bias, 
depending on which criteria are applied by laboratories in selecting isolates for referral or 
by reference laboratories in inviting isolate submission.  Isolates that are sent primarily 
for “epidemiological purposes”, usually referring to the determination of strain 
relatedness for outbreak control purposes, will be unlikely to represent the primarily 
sporadic bulk of invasive S. pyogenes infections.  Referral on the basis of atypical 
microbiological characteristics or clinical features would also present a biased group of 
isolates.  However, some countries have attempted to circumvent these problems of 
biased sampling by requesting submission of all invasive isolates, and as such referral 
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data may provide some important markers of trends in infection (Figure 2, modified from 
Efstratiou et al [59]).  Many countries in Europe have utilised both isolate referral-based 
and laboratory report-based surveillance systems in parallel (Tables 2, 3).   
 
Figure 2  Sterile site referrals and laboratory reports of S. pyogenes infection, 
England and Wales 1998-2002 
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Sources of information used for routine surveillance purposes have been periodically 
supplemented through invoking a period of “enhanced surveillance”, primarily to gain 
additional patient, clinical, microbiological and outcome measures.  Aside form the 
countries who participated in the Strep-EURO programme (see 4. Materials and 
methods), Belgium also initiated enhanced surveillance in 2004 following an observed 
sudden increase in invasive S. pyogenes disease cases detected through their 
laboratory surveillance system[60].  
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2.3. Definitions of severe S. pyogenes infection 
2.3.1. Definitions applied in different countries 
Definitions of ‘invasive’ or ‘severe’ S. pyogenes infections applied in different countries 
for surveillance purposes have varied to a considerable degree, with no agreed 
consensus definition existing.  Although ECDC has drafted and ratified among its 
member states case definitions for many infectious diseases, and is now collating 
surveillance data on them, S. pyogenes infections are not included as presumably not 
considered a sufficient priority[56;57].  The classification of S. pyogenes diseases put 
forward by a USA working group in 1993 has been adopted by several countries for 
surveillance or research purposes[24].  The classification divides these diseases 
according to five groups (Table 4, modified from [24]) 
 
Table 4  Classification of streptococcal infections 
I. Streptococcal toxic shock syndrome 
II. Other invasive infections: isolation of S. pyogenes  from a normally sterile site in 
patients not meeting the criterion for STSS 
A. Bacteraemia with no identified focus 
B. Focal infections with or without bacteraemia (included meningitis, peritonitis, 
pneumonia, puerperal sepsis, osteomyelitis, septic arthritis, necrotizing 
fasciitis, surgical wound infections, erysipelas, cellulitis) 
III. Scarlet fever 
IV. Non-invasive infections 
A. Mucous membrane 
B. Cutaneous 
V. Nonsuppurative sequelae 
A. Acute rheumatic fever 
B. Acute glomerulonephritis 
 
The USA Working Group further divided STSS into definite and probable according to 
whether a sterile site isolate was obtained or not, respectively.  Categorising STSS as a 
separate condition introduces a degree of overlap between the above categories, 
especially with group II, and precludes the possibility of describing the primary 
presentations of patients with STSS given the primacy of this presentation in their 
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hierarchical classification.  As such, and in consideration of STSS as a complication of 
streptococcal infection rather than a primary manifestation, many studies have classified 
STSS as a separate dimension across all clinical presentations. 
 
Adopting a clinically-based case definition for ongoing surveillance purposes is clearly 
more labour intensive than a definition based on microbiological results alone, and 
consequently adopted by few countries.  Many countries have tended to opt for a simple 
definition for surveillance purposes – isolation of S. pyogenes from blood and other 
sterile sites.  Two notable exceptions are Belgium, where isolates from deep ear sites 
were included in their routine case definition, and Australia (Victoria) where patients with 
pharyngeal isolates hospitalised for the treatment of quinsy were included. 
 
 
2.3.2. Impact of differences in case definition 
In comparing estimates of the overall burden of severe S. pyogenes disease between 
countries, it is important to take into account the different case definitions used for 
surveillance purposes.  Whereas routinely available data from the UK, Finland and 
France are based on blood culture isolates only (+/- CSF), most other countries monitor 
all sterile site isolates.  The majority of severe S. pyogenes infections result in 
bacteraemia, however, non-disseminated invasive infections have been found to 
account for around 10% of cases[6;73;103], although estimates as high as 24% have 
been documented[104].  This would therefore in part account for the differences in rates 
observed (Tables 2, 3).  Some countries, such as Norway, also monitor cases where the 
clinical presentation indicates a severe infection but without a sterile site isolate being 
obtained, increasing case numbers by around a quarter[52].  Surveillance in Belgium, 
which includes deep ear sites, adds approximately two-thirds more cases[57], although 
data for sterile site isolates are also available separately, as given in Table 2[61].   
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2.3.3. Sensitivity and specificity of surveillance systems 
Three key factors determine the sensitivity of national S. pyogenes surveillance systems 
1) failure to take a clinical sample at all, or pre initiation of antibiotic therapy 2) failure by 
the laboratory in correctly identifying the causative organism 3) failure to report the 
laboratory result (or refer the isolate) to the co-ordinating centre.  A further factor which 
may in the future impact on the sensitivity of microbiology-laboratory based surveillance 
is the use of near patient testing, should ward-based kits become available for analysis 
of blood cultures[105]. 
 
As an organism which is fairly easily identified by laboratories, specificity of laboratory 
results tends to be high, with results from the 2006/07 international external quality 
assessment scheme indicating 99% correct identification (1640 participants across 37 
countries)[106].  The biggest determinants of loss of sensitivity of surveillance systems 
come from either a failure to take clinical specimens or from a failure to report results to 
the co-ordinating centre.  With regard to the first of these, data illustrating the different 
thresholds or algorithms applied in clinical settings in different countries are difficult to 
come by.  Anecdotal reports suggest that in the resource-poorer countries within Europe, 
primarily those in the south, central and eastern Europe, clinical specimens are taken 
less commonly than among the wealthier nations, with patients being treated empirically 
on the basis of their symptomatology.  This is supported to a degree by data submitted 
from the participants of the European Antimicrobial Resistance Surveillance System 
(EARSS) on the rate of blood culture sets taken per 1000 bed-days (Figure 3, based on 
EARSS annual report 2006[107]).   
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Figure 3  Country-specific rates of blood culture sets taken per 1000 bed-days 
reported by laboratories participating in EARSS, 2004 
 
 
Loss of sensitivity due to under-reporting of laboratory diagnoses can be difficult to 
quantify unless independent sources exist to cross-validate.  In many countries coverage 
is known to be less than complete.  In some countries, such as the UK, coverage is very 
good although under-reporting by active laboratories is known to occur[108].  Studies 
which capture data from multiple sources allow us to evaluate the sensitivity of these 
systems.  For example, within the UK enhanced surveillance in 2000/01 of invasive 
Streptococcus agalactiae (Lancefield group B) disease captured and reconciled 
reference laboratory data and routine surveillance data with clinical (paediatrician) 
reports.  This identified an overall sensitivity of laboratory reporting (isolate referral and 
routine reporting combined) of 83%.  The degree of overlap between different sources 
can be used to perform a capture-recapture analysis to evaluate the true measure of 
incidence of a given disease[109].  However, unless the data sources are truly 
independent, this can easily overinflate estimates.  
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2.4. The burden of severe S. pyogenes infection at the turn of 
the millennium 
A recent review commissioned by WHO, published in 2005, estimated that 
approximately 660,000 cases of invasive S. pyogenes disease occur globally each 
year[110].  Measurement of incident cases has tended to be of the extent of most 
countries estimation of the burden of severe S. pyogenes disease.  Although such 
measures are of vital importance in detecting widespread changes, and reasonable for 
measuring the burden of acute diseases, they fail to provide a true measure of the 
burden of infection, which would require measuring the impact to the individuals, their 
families and to wider society.  Few studies have looked at the physical or psychological 
impact of these infections[111;112], and as such our evaluation of the burden of these 
diseases remains incomplete.   
 
 
2.4.1. Estimates of overall disease incidence in Europe 
Some interesting parallels emerge when comparing results from surveillance activities 
across Europe over the last decade.  Surveillance data from countries who have 
published five or more consecutive years’ results are shown in Figure 4.  Results from 
these primarily northern European countries show some interesting and not entirely 
uniform trends, although most exited the 1990s with higher rates of disease than they 
entered the decade.  Data from the Netherlands in particular contrast that from other 
countries, with rates of invasive S. pyogenes halving between 1995 (4.0 per 100,000) 
and 1999 (2.0/100,000), although an upturn was observed subsequently[113].  Most 
other countries showed reasonably consistent findings suggestive of an overall increase 
in incidence during the 1990s and into the 2000s, although trend patterns varied 
markedly from near linear to marked peaks and troughs.  Data from Scotland are among 
the most compelling, showing marked year-on-year rises from the mid 1990s onwards 
when rates of S. pyogenes bacteraemia rose from 1.5/100,000 in 1996 to 3.7/100,000 in 
2002, averaging at a 41% increase per year[85;86].  A more diluted rise in reports was 
also seen in England and Wales throughout the 1990s[114].  Data from Finland also 
showed a similar pattern, rising sharply from 1996 (1.2) to 2002 (3.0)[66].  Surveillance 
data from neighbouring Sweden (1993-1997) showed a less clear-cut pattern, rising 
sharply between 1993 and 1996 before dropping back again to a more stable annual 
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rate between 2.3 - 2.9/100,000[8;83].  Following the initial reports of a marked rise in 
severe clinical manifestations of S. pyogenes infection in the mid-1980s[15], rates in 
Norway showed an initial fall only to re-escalate around 1993[52].  More recent web-
published data indicate further sharp rises in rates of invasive S. pyogenes in Norway 
between 1996 and 1999 when rates of reports more than doubled to reach 
4.9/100,000[77].  Even more pronounced changes are apparent in Iceland, the smallest 
of the countries examined, where rates of invasive S. pyogenes swung from lows of 
around 1-2 per 100,000 to peaks above 6/100,000, the highest rates observed in any 
European country over this period.  Published data from Denmark showed further 
increases in the early 1990s to those identified towards the end of the previous 
decade[16;115], with the latest estimate from this period standing at 3.3/100,000[64].   
 
Surveillance data from France from the early 1990s were suggestive of a downward 
trend in invasive S. pyogenes infections, although recent reports indicate a rise between 
1999 and 2002[68].  Annual reporting rates in Belgium showed marked rises between 
1994 and 2000[61], from less than 0.5 invasive S. pyogenes cases per 100,000 in the 
mid 1990s to approaching 1/100,000 in early 2000s.   
 
Figure 4  Country-specific annual rates of invasive S. pyogenes infection in 
Europe, 1990-2002 
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It is of interest to note the pattern of the changes in rates of invasive S. pyogenes reports 
within countries.  Whereas countries such as Norway, Sweden, Iceland and the 
Netherlands showed quite marked up- and downswings in their rates of disease, other 
countries such as the UK and France have not seen such marked changes.  It may be 
that outbreaks of invasive S. pyogenes disease are masked in national data given the 
larger population size of these countries, although population density is also likely to be 
an important factor in determining spread.  Regional analyses and further microbiological 
characterisation of isolates would need to be undertaken to confirm if this is the case.  
Regardless of the patterns of invasive S. pyogenes disease, there is general suggestion 
of increasing rates of infection across Europe since the beginning of the 1990s.   
 
The estimates of disease incidence will of course be influenced by a number of 
artefactual factors, including the choice of case definition as discussed in 2.3.2. Impact 
of differences in case definition and coverage of the surveillance systems, discussed 
in 2.3.3. Sensitivity and specificity of surveillance systems.  Even with these factors 
borne in mind, there is a fair degree of variation between countries over this period, with 
rates of S. pyogenes bacteraemia between 1.3 and 3.6/100,000, and rates of invasive S. 
pyogenes (all sterile sites) infection between 0 and 4.8/100,000.  To what extent these 
lower estimates reflect true differences in incidence or other methodological factors, is 
unclear. 
 
2.4.2. Estimates of overall disease incidence outside Europe 
Of the developed countries outside Europe, surveillance data estimating incidence of 
infection have been published from Australia, Canada and the USA.  Estimates of 
severe S. pyogenes disease incidence from Australia and the USA have been broadly 
similar to those from within Europe during the early 2000s, around 3-4 per 100,000[1;2].  
Data from the USA Active Bacterial Core system offer a longitudinal picture, which 
shows no clear trend pattern during the early 2000s, fluctuating between 3.2 and 
3.9/100,000[1].  Disease estimates from eastern Canada (Ontario, Québec) have been 
similar to those from the USA, although interestingly those from western Canada 
(Alberta) have tended to yield higher rates up to 5.7/100,000[3;4;90].  This may be 
explainable through differential participation in surveillance across Canada, although it 
could conceivably reflect a true difference in incidence, for example due to the climatic 
differences between the more dry and arid west than the east.  Of the less developed 
 22 
countries, disease incidence estimates have been published for Fiji and Kenya, the latter 
restricted to children, both of which have indicated high rates of infection, 12/100,000 in 
Fiji and 29/100,000 among <5 year olds in Kenya[92;97]. 
 
2.4.3. Overview of trends within and outside Europe 
Data from within Europe has tended to show more consistent trends indicative of an 
increase in incidence during the 1990s and 2000s[31].  Outside of Europe, most of the 
longitudinal data has come from the USA, which show relative stability over this period, 
although reporting rates similar or even slightly higher than reported by European 
countries[1;116;117].  Reports outside of the USA have tended to indicate increases in 
rates of disease during the 1990s[4;88]. 
 
It is somewhat unclear what the key drivers are for the increases noted by most 
countries.  Discounting artefactual causes, there are several possible hypotheses, 
including a) an increased circulation of more pathogenic serotypes b) an increase in 
virulence of the (same) circulating serotypes c) an increase in carriage due to decreased 
antibiotic prescribing d) an increase in transmission due to behavioural/sociological 
changes affecting mixing patterns or crowding e) an increased susceptibility due to 
environmental changes f) a decrease in immunological protection due to lower 
transmission rates in childhood.  
 
2.4.4. Mortality associated with S. pyogenes infection 
An total of 163,000 deaths attributable to invasive S. pyogenes disease have been 
estimated to occur each year globally, ranking ninth among infectious causes of 
death[110].  Between 47 and 77,000 deaths annually have been estimated to be due to 
maternal sepsis[46;118], representing between 8 and 12% of all maternal deaths in 
developing countries, and 2% in developed[118].  Of these maternal sepsis deaths, a 
sizeable proportion are likely to be due to S. pyogenes.  
 
Case fatality rate measurements have varied substantially between studies, ranging 
from 7-23% of patients[2-8]. These differences are due in part to the way this is 
measured, for example the post-infection follow-up period or whether cause-specific or 
all cause mortality is measured.  More fundamentally, overall measures of mortality will 
be highly dependent on the different types of disease presentation, serotypes 
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responsible and the patient groups affected, with young adults tending to have the better 
outcome than children and the elderly, and those with necrotizing fasciitis (15-45%), 
pneumonia (20-38%) or who develop STSS (35-81%) the poorest 
survival[4;6;8;11;89;116;119;120].  Measurement biases can also be introduced where 
this information is captured by questionnaire survey, as the cases with the worst 
prognosis are less likely to be missed by clinicians or less likely to be noted as having an 
uncertain outcome.  Using external sources of information on mortality, such as death 
registrations linked to the patient records, provides a more robust means of measuring 
case fatality rates.  Where the cases represent all those occurring in a given population, 
these linked deaths can also be translated into a population measure of mortality (deaths 
per 100,000 population), providing a useful comparator to other competing causes of 
death[110]. 
 
2.4.5. Microbiological characteristics of pathogenic strains  
S. pyogenes isolates are typically characterised according to their cell wall T- and M-
proteins, with the latter offering greater ‘discriminatory power’ over the T-protein.  Typing 
schemes are based on either serological identification of the T- and M-proteins, or more 
commonly genotyping of the emm gene which encodes the M-protein.   
 
Within any given population at any given time, an array of different emm/M-types are 
found to circulate, determined by competition between strains in combination with 
immunological memory of susceptible hosts.  The diverse range of emm/M-types is in 
itself a likely reflection of an evolutionary strategy to evade the host immune response, 
with novel types continuing to emerge.  Some strains appear to be more successful 
given their relatively high frequency in diverse populations, namely M1, M3, M28, M12, 
M87, M89.  M1 and M3 have long since been associated with particularly severe 
infections such as necrotizing fasciitis, with influxes in either strain being associated with 
a general increase in incidence of infection and associated mortality[15;20;121].  It is 
unclear whether these serotypes are equally successful as colonisers and the relative 
high frequency of severe disease caused by them is a straightforward reflection of their 
frequency as colonisers at any given time as few robust studies have looked at this.  
Many studies have compared the frequency of emm/M-types causing superficial and 
severe infections in given population at the same time[8;93;122-124], although these 
tend to be based on collections of referred specimens which may well not reflect the full 
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array of either all superficial infections or colonising strains.   One study which did obtain 
a representative sample of carriage, pharyngitic and invasive strains was carried out in 
Australia, and found that emm1 strains were significantly associated with pathogenic 
potential, and emm12 were significantly less pathogenic[41]. 
 
Although S. pyogenes isolates have remained sensitive to penicillin[125], continued 
monitoring of penicillin resistance is essential, given the evolution of resistance in other 
members of the genus which share the same ecological niche.  Resistance to other 
important therapeutic agents, notably clindamycin and erythromycin (see 2.6 Current 
treatment strategies), has been observed at low levels in many countries.  Although a 
wealth of published literature on resistance in organisms causing superficial infections 
have been published, and have formed the basis of international surveillance activities 
via the SENTRY and PROTEKT schemes[126;127], fewer publications provide estimates 
for isolates involved in invasive disease, which may conceivably have different 
resistance patterns to superficial strains.  Biases can also be introduced where 
microbiological sampling occurs after initiation of treatment with antibiotics. 
 
Estimates of macrolide resistance in S. pyogenes strains causing invasive disease in 
Europe during the 1990s and early 2000s showed considerable variation, a possible 
reflection of differences in macrolide consumption at a population level[128].  Within 
country changes in macrolide consumption, albeit those that result from variation in 
prescribing according to seasonal patterns of S. pyogenes disease, or as part of longer-
term programmes to reduce macrolide consumption, have been shown to decrease 
erythromycin resistance levels[65;129].  However, the impact on isolates causing 
invasive disease has not been demonstrated.  Most countries in Europe have reported 
erythromycin resistance in less than 10% of isolates (Table 2).  Notable exceptions are 
in France and Italy where over 20% of isolates were found to be resistant, possibly 
linked to their high levels of macrolide consumption[128].  Prevalence of erythromycin 
resistant organisms involved in invasive disease is increasing in some countries[67;130].  
Outside Europe, estimates of macrolide resistance in invasive isolates collected during 
the 1990s and 2000s varied from 0.4% to 11% (Table 3). 
 
Fewer large-scale studies have reported rates of clindamycin resistance.  This may be in 
part due to practical considerations as isolates found to be erythromycin resistant have 
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to have clindamycin resistance tested alongside erythromycin to check for inducible 
resistance[131].  A further reason may be the high cost of clindamycin[125]. Of the 
studies that have reported clindamycin susceptibility, 22% of invasive isolates in Italy 
1994-96 were reported as resistant[27], and 12% in a small subset of isolates in 
Spain[132].  Substantially lower estimates have been published in Poland (5%), Japan 
(4%), UK and Ireland (1%) and Australia (no resistance)[2;79;96;133].  Data from non-
invasive isolates show even greater variability, from 30% in Portugal[80], to 3% or less in 
Brazil, Bulgaria, Greece, New Zealand, Russia and the USA[81;99;134-137]. 
 
2.5. Control of severe S. pyogenes infection 
In the absence of a licensed vaccine, control measures for severe S. pyogenes infection 
have been reliant on targeted antibiotic prophylaxis and measures to decrease 
transmission via fomites or person-to-person spread.  The design of such measures to 
prevent primary or secondary cases of severe S. pyogenes infection rests on the ability 
to identify any groups or activities conveying increased risk of infection to target control 
measures.  As infections which are largely sporadic, occur in a broad cross-section of 
the population and are generally rare, opportunities for primary prevention of severe S. 
pyogenes disease are rather limited.   
 
2.5.1. Factors predisposing to severe S. pyogenes infection  
Our identification of factors which predispose to severe S. pyogenes infection is 
somewhat curtailed as few studies have applied rigorous epidemiological study methods 
to examine this, comparing exposures in cases to recruited controls or to normative 
(population) data.  In part, this may be due to the array of different proposed risk factors, 
as deriving sufficient statistical power to evaluate many of the less common exposures 
would be difficult as the number of ‘exposed’ cases will remain small.  For this reason, 
factors such as premature birth, clearly posing a particular risk of severe sepsis, has not 
been formally evaluated by comparison to a reference group (see Table 5).  In contrast, 
some exposures such as skin trauma are so common place as to require a very large 
sample of cases and controls to observe any meaningful difference, or comparison to 
normative data which would be hard to come by.  As such, only a handful of factors have 
been identified by analytical means as conferring heightened risk of infection: age, male 
sex, ethnicity, HIV infection, varicella, smoking, household crowding, diabetes, heart 
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disease, injecting drug use, malignancy and pregnancy (Table 5).  Most of these risk 
factors are reasonably non-specific to S. pyogenes infection, and their relative 
importance is likely to change over time as the prevalence of the underlying conditions 
change in frequency.   
 
Circumstances which breach the skin barrier provide a portal of entry for the organism, 
albeit traumatic or surgical wounds, chronic infection sites or chickenpox lesions.  
Injecting drug users are one group at particularly high risk, as a direct result of injection 
site contamination or indirectly as a result of straitened living circumstances.  Many 
studies have identified men as being at higher risk of severe S. pyogenes infection than 
women, although again this seems to be the case for invasive bacterial infections in 
general[138;139].  Cases of necrotizing fasciitis are particularly more common in males 
though[140], possibly a reflection of occupational risk given the importance of skin 
trauma as a risk factor.  Abattoir workers and meat handlers have also been 
documented as being overrepresented among cases of skin sepsis[141-143].  Whether 
this increased vulnerability is due to increased risk of skin trauma from working with 
knives or connected with meat itself is unclear, although other occupational groups at 
risk of minor trauma do not seem to experience outbreaks of S. pyogenes skin sepsis as 
commonly as meat handlers.   
 
A number of patient factors have also been identified as conferring increased risk of 
severe S. pyogenes infection.  These include medical and other conditions affecting 
immune function, such as diabetes, malignancy and alcoholism.  The elderly and to a 
lesser extent young children have a higher risk of infection than young adults.  
Interestingly, an exception is seen in surveillance data from Alaska which indicates 
higher rates in children (<2y; 35/100,000) than the elderly (65y+; 14/100,000) among its 
native population[102].  Rather controversially, use of non-steroidal anti-inflammatory 
drugs has been linked to development of necrotizing fasciitis although not consistently 
across all studies[144].  
 
Many countries worldwide have reported a higher incidence of severe S. pyogenes 
disease in particular ethnic groups.  Studies from North America have found higher rates 
of infection in black Americans[116;117], native Americans[6] and aboriginals in the 
arctic region of Canada[89] compared to white European settlers.  From the pacific 
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regions, indigenous Australians[88] and to a lesser extent Fijians[92] have also been 
found to be at heightened risk of invasive disease.  Although few such studies have 
been carried out within the European region, in part owing to political sensitivities in 
some of the more active northern countries, two studies from Israel report high rates of 
infection in its Bedouin and Jewish population compared to estimates from western 
Europe[74;75].  Given the disparate nature of the populations found to be at heightened 
risk, it may be that different factors explain the increased susceptibility in different 
groups.  Darkly pigmented skin prevents the synthesis of calciferol (vitamin D) and as 
such dark skinned individuals residing in non native areas with less intense UV light 
exposure are more prone to diseases linked to vitamin D deficiency[145].  Given the 
connection between vitamin D and immune function[146], this could in part provide an 
explanation for the increased rates of infections in black Americans.  Non genetic factors 
could also play a role, given that customs, living conditions, prevalence of diabetes and 
alcoholism differentiate these populations from white Europeans.   
 
Of the risks posed to women, childbirth is amongst the highest as a result of bacteria 
colonising the vagina contaminating traumatic wounds incurred during the birthing 
process.  Ascension of these bacteria into the uterine sac following rupture of 
membranes presents a further risk to the unborn child[147]. 
 
Given the characteristic transmission dynamics of S. pyogenes, most severe infections 
occur sporadically, with the affected individual having no close contact with another 
individual with superficial or severe disease; the organism is presumably transmitted 
from an asymptomatic carrier.  Close contact with individuals symptomatic of superficial 
infection, such as pharyngitis, have been shown to increase risk of severe 
infection[148;149], as has close contact with individuals with severe disease, albeit an 
uncommon occurrence[89;150-152].   
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Although a number of risk factors have been identified, as outlined above, one of the 
distinctive features of severe S. pyogenes infections is its ability to affect the otherwise fit 
and healthy.  Between 17-31% cases occur in individuals with no evidence of any 
particular risk or predisposing factor[16;28;101;117]. 
 
 
2.5.2. Seasonal patterns of infection 
One of the defining characteristics of S. pyogenes infections are the distinctive seasonal 
patterns in incidence of disease (Figure 5, HPA).  Invasive disease patterns typically 
have a higher frequency between late Winter and early Spring, and substantially lower 
frequency in the late Summer/Autumn, a finding fairly ubiquitous across 
Europe[15;16;76], with few exceptions reported[111]. Similar patterns are also seen for 
scarlet fever and streptococcal pharyngitis[160;161].  Impetigo tends to have a summer 
peak, although its aetiology is divided between staphylococci and streptococci, and may 
be closely tied to insect bites[162].  Outside of Europe, marked and very similar 
seasonality has been reported from the USA[116;117] and Canada[3;90].  Invasive 
pneumococcal disease shows a very similar seasonal pattern[163], and interestingly, a 
broadly similar pattern has been described for Streptococcus suis infections in pigs[164]. 
 
The explanations behind these seasonal patterns remain rather unclear.  Possible 
explanations include environmental factors, such as impact of climatic changes on 
mucosal defence barriers or cumulative ultraviolet light exposure on immunological 
function, or indirectly as a result of seasonal patterns of viral respiratory infections which 
may induce vulnerability to S. pyogenes infection[165].  Other factors which may be of 
relevance include the influence of weather conditions on social and behavioural patterns, 
in particular indoor gathering vs outdoor activity, and similarly the impact of the 
academic term-holiday cycle on transmission patterns.  The impact central of heating 
systems in lowering humidity may also be a contributing factor.  Interplay of different 
factors could explain the changes seen at different times of the year. 
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Figure 5  Weekly counts of scarlet fever notifications and S. pyogenes bacteraemia 
diagnoses (all ages), England & Wales 1997-2002 
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2.5.3. Control of S. pyogenes in community settings 
Opportunities for primary prevention of severe S. pyogenes infection in community 
settings are rather limited.  As an important risk factor for infection in children, prevention 
of varicella could represent one of the few opportunities for primary prevention.  
Estimates from Canada suggest that 10% of paediatric invasive S. pyogenes cases 
could be prevented through universal childhood varicella vaccination[166].  At present, 
only a limited number of countries in Europe have opted to include varicella vaccination 
within their childhood immunisation programmes (Austria, Cyprus, Germany, Italy, 
Spain, Switzerland)[167]. 
 
Where resurgences of infection occur in particular population sub-groups, such as 
injecting drug users, opportunities for targeting advice on prevention or detection of early 
signs of infections can arise.  In outbreak situations, measures to prevent further cases 
will be dependent on the specific situation and what intelligence is available at the time 
on which to base decisions, but are likely to include antibiotic prophylaxis to contacts.  
For example, outbreaks of soft tissue infection have also been associated with military 
training camps or contact sports, where the close proximity of susceptible hosts coupled 
by activities which may result in localised skin trauma provide ideal circumstances for 
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facilitating spread[168].  Under such circumstances, control measures are likely to 
include decontamination of shared facilities along with advice on not sharing towels and 
other personal items. 
 
Designing secondary control measures for the prevention of cases in household 
contacts is rather hampered by a lack of precise data evaluating the risk to household 
contacts.  Obtaining such data would necessitate the identification of all linked cases 
within a given population at a given time, along with information on how many individuals 
were at risk in the given household and any particular risk factors among each of these 
members.  As such, estimates are likely to have a wide margin of error given the poor 
sensitivity of many surveillance systems to identify linked cases and practical difficulties 
in obtaining information regarding the household constitution.  Of the studies which have 
tried to systematically identify household clusters in a given population over a defined 
period of time, only 5 household pairs have been identified by the USA and Canada 
combined and a further 5 in the UK[89;91;151;152].  Given these small sample sizes, 
estimates of risk to household members are imprecise, although certainly higher than 
among the general population.  Even with this information, a difficult and subjective 
judgement needs to be made by policy makers regarding the threshold of ‘numbers 
needed to treat’ to prevent a case.  As a result, different countries have differentially 
evaluated the risk to household cases from 66 to 294 per 100,000 and consequently 
have adopted different strategies for secondary control in household settings[169].  In 
Canada, antibiotic prophylaxis is recommended for all household members where a 
case of severe S. pyogenes infection arises in the community [89] whereas in the USA 
prophylaxis is only recommended where one or more household members is at high risk 
of infection[150].  Within Europe, the UK was the first country to publish guidelines on 
the management of community contacts, with the recommendations for prophylaxis 
being restricted to mothers and infants where the other develops an infection, or 
institutional/household settings where 2 or more invasive cases arise[125;152].  Norway, 
France and Ireland have since published their own guidance[170-172].  The 
effectiveness of any such measures will be limited however, as clustered cases often 
arise very close together in time[173], limiting the opportunity for administration of 
prophylaxis or early treatment.  All countries emphasise the importance of providing 
household members with information on possible early signs of invasive S. pyogenes 
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infection and the course of action to be taken should they arise, which in itself may be as 
effective a measure as chemoprophylaxis. 
 
 
2.5.4. Control of S. pyogenes in hospital and institutional settings 
The foundations of hospital infection control were based on the observations of 
Semmelweiss that effective hand hygiene and droplet precaution measures could lower 
the risk of puerperal infections and post-partum mortality[48].  Although this eventually 
paved the way for the introduction of modern-day hospital hygiene guidelines, it is of 
interest to note that guidance specific to the control of S. pyogenes infections in 
maternity settings does not exist in many countries[174].  Clusters of invasive S. 
pyogenes disease in maternity settings continue to occur, on occasion resulting in the 
death of otherwise healthy young women[8;13;52;175]. 
 
Guidelines for the control of S. pyogenes in hospital settings in general do exist in 
France, Ireland, Sweden, Canada and the USA, with France making specific 
recommendations for maternity units[89;150;172;176;177].  Recommended measures 
for investigating hospital clusters in maternity or other settings range from screening of 
staff caring for the affected patients to all unit staff and their household members[174].   
 
Outbreaks of severe S. pyogenes infection in a range of institutions have been reported, 
in particular residential facilities providing care for the elderly owing to the vulnerability of 
these residents[91;178-181], necessitating the use antimicrobial prophylaxis to break the 
cycle of transmission and/or provide early treatment[182].  A study in Atlanta found that 
nursing home residents were eight times more at risk than age-matched counterparts 
residing in the community[101].  Schools, nurseries and other childcare facilities have 
also been the focus for clusters of invasive disease, especially concomitant to outbreaks 
of varicella[40;183].  Control measures in such instances can involve vaccination to limit 
the scale of the varicella outbreak and secondary bacterial infections, alongside 
antibiotic prophylaxis.  Schools can also provide a pool of carriers to seed invasive 
infections among family contacts, as seen in one outbreak in the USA[38], offering 
opportunities for chemoprophylaxis of the key reservoir for an outbreak.   
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2.5.5. Vaccines under development 
Given the nature of these infections, vaccination provides a more realistic opportunity for 
primary prevention, although not without some possible limitations (see 6.1.7 Potential 
impact of vaccine candidates).  Two vaccines are currently under trial, a hexavalent 
preparation covering M-types 1, 3, 5, 6, 19, 24 and 26-valent vaccine covering 1, 3, 5, 6, 
19, 24, 29, 14, 12, R28, 18, 2, 43, 94, 22, 11, 59, 33, 89, 101, 77, 114, 75, 76, 92[184-
186].  Phase II testing of the 26-valent vaccine in adults have shown promising 
results[185;187], with further test results from children awaited.   
 
2.6. Current treatment strategies  
2.6.1. Antibiotic therapy 
Given that S. pyogenes has to date remained sensitive to penicillin, this remains the 
first-line treatment of choice once S. pyogenes has been identified as the cause of the 
sepsis[34;188].  Using clindamycin in combination with penicillin G (benzylpenicillin) has 
been shown to inhibit the activity of virulence factors, lowering the risk of STSS[34].  
Where penicillin allergy is reported, cephalosporins or vancomycin can be used as an 
alternate[188].  Speed of initiation of intravenous antibiotic therapy is essential given the 
rapidity of the clinical course[9-11].  Delayed treatment as a result of misdiagnosis of key 
signs of deep seated S. pyogenes infection has been associated with increased 
likelihood of death[13;157;183]. 
 
2.6.2. Intravenous polyspecific immunoglobulin G 
Whilst there is some evidence that intravenous polyspecific immunoglobulin G (IVIG) 
may improve the outcome of patients with sepsis and septic shock[189;190], the 
therapeutic value of its use specifically for the treatment of severe S. pyogenes infection 
remains undemonstrated. An observational study carried out in Canada between 1992 
and 1995 measured a decreased 30 day mortality in patients treated with IVIG, although 
survival was unusually high in the untreated group[191].  A recent randomised controlled 
trial in Sweden was prematurely stopped owing to a lack of power for the study to 
evaluate a difference between its control and treatment arms due to low numbers of 
patients recruited[192].  Despite the lack of robust evidence of efficacy, it remains a 
recognised adjunct to antibiotic therapy[188;193]. 
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2.6.3. Surgery and other therapeutic approaches 
Where tissue necrosis or gangrene is suspected, surgical exploration is essential along 
with immediate debridement of affected and surrounding tissue, even if likely to render 
the patient vulnerable to surgical wound infection[34].  Other more novel approaches 
include use of hyperbaric chambers for the treatment of necrotic infections, which 
facilitate blood supply to necrotic tissue through the use of hyperbaric oxygen[194]. 
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3. AIMS OF THE STUDY
 
In light of recent reports indicating global changes in the epidemiology of severe clinical 
manifestations of S. pyogenes infection, and given the disparate and disconnected 
surveillance activities across Europe, leading microbiologists from across Europe formed 
a unified network (Strep-EURO) to take forward a programme of work relating to severe 
S. pyogenes disease.  The overall aim of this study was to substantially improve our 
understanding of the epidemiology of severe S. pyogenes disease in Europe.  This 
would be achieved through the following objectives: 
 
· To measure and compare the overall and disease-specific burden of S. 
pyogenes disease in eleven countries across Europe 
· To identify and compare key risk groups in each country to potentially identify 
targets for public health intervention 
· To identify factors associated with development of STSS as a means of directing 
future basic research into disease pathogenesis 
· To undertake an in-depth analysis of cases occurring in UK injecting drug users 
according to emm types, clustering, clinical presentations and outcome to better 
understand the possible modes of transmission and burden of disease in this 
group 
· To better understand clinical, demographic, microbiological and other possible 
predictors of mortality  
 
Pooling of data from the eleven countries would yield a powerful base to examine the 
interrelation between the host and pathogen factors by providing a large sample size for 
analysis.  This in turn would yield findings of value in directing public health action, as 
well as directing future research.  A particular focus was placed on UK cases given the 
additional clinical information provided for these cases and the evident differences in the 
epidemiology of these infections in the UK compared to any other country. 
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4. MATERIALS AND METHODS 
4.1. Overview of the Strep-EURO project 
Funded by the Fifth Framework Programme of the European Commission’s Directorate-
General for Research (QLK2.CT.2002.01398), the Strep-EURO network was launched 
in September 2002 (www.strep-euro.lu.se).  Twelve participants across eleven countries 
took part in Strep-EURO (two from Sweden), with overall co-ordination provided by the 
University of Lund in Sweden.  The programme of work was divided into seven work 
packages (lead country given in brackets): 
WP1  Establishment of a surveillance and reference laboratory network across EU and 
Associated Countries (Lund, Sweden) 
 WP2  Data management (Finland) 
 WP3  Laboratory diagnostics of GAS (UK) 
 WP4  Clonal identification of streptococci (Germany) 
 WP5  Virulence characteristics of invasive GAS strains (Lund, Sweden) 
 WP6  Susceptibility of streptococcal isolates to antibiotics (Denmark) 
 WP7  Project management (Lund, Sweden) 
 
This PhD thesis will focus on data generated through the activities in WP1, 2, 3 and 6. 
 
4.2. Surveillance methods 
4.2.1. Case definitions 
Cases were defined as patients with S. pyogenes isolated from a normally sterile site, or 
non-sterile site in combination with clinical signs of streptococcal toxic shock syndrome 
(STSS).  Within the UK a broader case definition was applied with the inclusion of 
patients with non-sterile site isolates with one of the following severe presentations (I, III, 
IV): pneumonia, necrotizing fasciitis, puerperal sepsis, meningitis or septic arthritis.  
These additional cases were not transferred to the central database but were retained 
for UK analyses only. 
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The 1993 Working Group on Severe Streptococcal Infections’ definition of STSS was 
used[24]: hypotensive shock in conjunction with two or more specified clinical indicators 
(renal impairment, abnormal liver function, respiratory distress, erythematous rash, 
disseminated intravascular coagulopathy, soft tissue necrosis), with cases of ‘definite’ 
(those with sterile site isolates) and ‘probable’ (those with non sterile site isolates) STSS 
combined. 
 
4.2.2. Case ascertainment 
All participating countries undertook prospective enhanced surveillance between 1st 
January 2003 and 31st December 2004 to identify cases of severe S. pyogenes disease 
diagnosed during this period.  Methods employed to identify cases varied by country; 
most identified cases through invited submission of isolates from local microbiology 
laboratories to the national streptococcal reference centre.  The majority of participants 
identified cases from across the country, with some exceptions as noted in Table 6.  
Three countries (Finland, Sweden and the UK) identified cases using two separate 
sources to maximise case ascertainment, with cases reconciled to avoid duplicate 
counting.   
 T
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4.3. Study data collected 
4.3.1. Clinical and risk factor data 
A standardised surveillance dataset was defined, comprising demographic, clinical and 
risk factor information for cases collected through the questionnaire disseminated by 
each participant.  The following items were included in the questionnaire: 
 
· Country 
· Unique case number 
· Sex 
· Age  
· Region 
· Date of sample collection 
· Specimen site/s 
· Clinical condition/s: no focal symptoms, STSS, necrotizing fasciitis, cellulitis, arthritis, 
puerperal sepsis, meningitis, other 
· Treatment/s and procedures: admitted to ICU, ventilatory assistance required, surgery 
performed because of GAS infection, other 
· Additional clinical markers: hypotensive shock, coagulopathy, renal impairment, liver 
abnormality, respiratory distress, erythematous rash, soft-tissue necrosis, other 
· Outcome due to GAS infection: vital status at 7 and 30 days 
· Predisposing factor/s: diabetes, current injecting drug use, chickenpox, 
immunosupression, chronic skin lesions/wound, surgical operations within 7 days, 
hospital acquired infection (hospital care within 48 hours), other 
· Cluster or outbreak identifier 
 
Additional items were optionally included by some countries (see Annex 10.1 detailing 
the UK questionnaire).  In Denmark and Sweden, as enhanced surveillance was already 
in place, existing questionnaires were used with any differences to the study 
questionnaire items noted for future analysis.  Mortality outcome data was obtained 
through the national deaths registry in Denmark, Finland (2004 only) and the UK, 
otherwise through the questionnaire.  For the UK, mortality information was available 
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from both the questionnaire and from the deaths registry (obtained from the Office for 
National Statistics).  Information placed on patients’ death certificates was available for 
UK cases (IV), namely date of death, place of death and certified cause/s of death 
(underlying and contributory causes).  The UK questionnaire distinguished deaths 
according to whether they were attributed to S. pyogenes infection (as the main or 
contributory cause) or not.  
 
In Finland, clinical and risk factor data were collected by an infectious disease clinician’s 
review of patient medical records in a predefined area (Pirkanmaa health district, 
Western Finland, population of 440,000). 
 
4.3.2. Collection and characterisation of isolates 
Isolates were collected by the national reference (or designated central) laboratory for 
each of the 11 countries.  Isolates were characterised according to their M protein using 
conventional serological methods (M type immunodiffusion and anti-OF typing) or emm 
gene typing (emm PCR ELISA, emm reverse line blot hybridization or gene sequencing) 
[195-197]. Antibiotic susceptibility testing was carried out by the central reference 
laboratory for all countries except the UK, where testing was undertaken by the original 
referral laboratories according to local standard operating procedures, primarily using 
disc diffusion.  Susceptibility testing by the national reference laboratories was 
undertaken using E-test, disc diffusion or agar dilution with MICs interpreted against 
standard breakpoint references (CLSI, SRGA, BSAC and CA-SFM)[198].  Isolates were 
tested against erythromycin, tetracycline, clindamycin and optionally against linezolid, 
dalfopristin/quinopristin, telithromycin and moxifloxacin. 
 
Three external quality assessment studies were included within the remit of the Strep-
EURO programme, for serological and molecular (emm) typing, PFGE subtyping and 
antimicrobial susceptibility determination using phenotypic and genotypic methods.  
Results from these demonstrated equivalence of techniques adopted in each country 
removing the need for further standardisation[195;198]. 
 
4.3.3. Collation and validation of study data 
Data were formatted and transferred to the data hub in Finland according to a specified 
protocol, and stored in a secure SQL Server database.  Further validation checks were 
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undertaken on the combined data to identify any logical inconsistencies in the data 
supplied and to ensure all cases met the case definition.  Cases marked as having 
STSS were checked to ensure this definition was met according to the clinical indicators 
given, whilst these same indicators were also used to identify cases not marked as 
STSS but which met the case definition.   
 
4.4. Analysis of project data 
All comparative analyses across the Strep-EURO participating countries were based on 
cases meeting the agreed case definition and using the standardised dataset.  Case 
fatality ratios were based on all cause mortality.  Analyses of case fatality made on the 
UK cases alone were restricted to attributable deaths (main or contributory cause) for 
papers I and III.  For paper IV, analyses were based on all-cause mortality. 
 
Additional cases captured in the UK from the expanded case definition, along with 
additional data items collected from the UK questionnaire or through linkage of records 
to the national deaths registry (IV), were not included in comparative analyses.   
 
Data were extracted from the SQL Server and imported into STATA™ software (release 
8.2 College Station, Texas: Stata Corporation, 2005) for statistical analysis.   
 
 
4.4.1. Statistical methods 
Descriptive statistics were undertaken, with χ2 and Kruskal-Wallis tests being applied to 
test for statistical significance of differences between subgroups in proportions and 
distributions of continuous variables respectively, and linear regression to evaluate 
associations between continuous variables (Pearson correlation for binomial data and 
Spearman’s Rank for rates).  Rates of infection were calculated using mid-year resident 
population estimates as denominators for the respective countries for each year (or 
closest available year) according to age and sex.  Exact 95% confidence intervals (CI) 
around rates and rate ratios were calculated according to the Poisson distribution (I, II), 
and according to Binomial distribution for proportions (II, IV).  
 
UK cases were linked to death registrations using probabilistic linkage methods (IV) to 
circumvent any problems of missing or erroneous identifiers within the surveillance 
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reports[199].  Deaths from all causes occurring up to 30 days after infection were 
identified from this linkage.  Certified cause/s of death (underlying and contributory 
causes) were analysed according to ICD-10 codes provided and time between diagnosis 
and death was measured from the date the culture positive specimen was taken (post-
mortem cultures were included with those taken on the day of death).  Kaplan-Meier 
survival curves were generated to describe survival from date of diagnosis.  Survival 
between subgroups was compared using a non-proportional test for equality of survivor 
function (Peto-Peto-Prentice). 
 
Unconditional logistic regression analyses were undertaken to evaluate associations 
between outcomes of interest and potential explanatory variables (II, III, IV).  Models 
were analysed in a backward step-wise fashion, with removal of non-significant variables 
at each stage in order of magnitude of the p-value obtained from Likelihood Ratio tests 
(LRT).  All variables with an LRT p value of below 0.2 were kept until the final model, 
after which only variables with p<0.05 were retained. 
 
 
4.4.2. Standardisation of rates  
Overall country rates were age-standardised according to the European Standard 
Population (II, see Annex 10.2).  This was undertaken to facilitate comparison of rates 
between countries whose demographic population structure may vary and in part explain 
differences in crude rates, given the association between age and risk of infection. 
 
 
4.4.3. Geographical mapping 
Country-specific rates were mapped using MapInfo Professional© (version 8.0, release 
build 18 Troy, New York: MapInfo Corporation, 2005).  This software was also used to 
calculate distances between diagnosed cases in the UK to identify clustering, when 
combined with temporal information (III).  Potential clusters were defined as cases 
occurring with 10km of each other and diagnosed with 30 days. 
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5. RESULTS  
5.1. Overview of cases identified across Europe 
During 2003 and 2004, a total of 5522 cases meeting the definition for severe 
Streptococcus pyogenes infection were identified across the eleven participating 
countries (Table 7).  Of these 5522, 5462 (99%) had sterile site isolates submitted, and 
the remainder included on the basis of having STSS.  Eight-six per cent of cases (4771) 
had a blood culture positive isolate, 4% (224) joint isolates, 1% from CSF (50) and 11% 
(627) from other sterile sites (Figure 6).  
 
Figure 6  Site of S. pyogenes isolation from cases of severe infection, Europe 2003-04 
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The number of cases identified in each country varied from four in Cyprus (0.1% of all 
cases) to 3630 in the UK (66% of all cases).  Considerable variations in age distributions 
were seen between countries, with no clear geographical pattern.  Cases in Greece 
were primarily drawn from a children’s hospital in Athens owing to low participation in 
other hospitals, resulting in a largely paediatric sample.  Excluding Greece, significant 
variations in age distributions between countries were apparent, (Kruskal-Wallis Test χ2(9 
df)=261.47; p<0.001), cases being notably older in Sweden (median 70 years) than all 
other countries (Table 7).  Overall, 53% of severe S. pyogenes cases were male, with 
most countries observing slightly higher numbers of cases in men than women, with no 
significant variation between countries in this ratio (χ2(10 df)=17.39; p=0.07).   
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5.2. Rates of severe S. pyogenes infection 
Rates were calculated for all countries except Germany, France and Greece owing to 
incomplete participation among hospitals across these countries’ catchment areas or 
within any definable catchment zone.  Of the remaining eight countries, rates were 
calculated nationally for Cyprus, Czech Republic, Denmark, Finland and Sweden and for 
the following areas in other countries - Italy (Lombardia region), Romania (Bucharest 
and 7 other counties), UK (England, Wales, Northern Ireland, Channel Islands and Isle 
of Man).  Of these eight countries, age-standardised rates were calculated and 
compared to crude rates.  Standardisation had the biggest impact on Sweden in 
reducing its rate from 3.10 to 2.28 per 100,000 population (Figure 7). 
 
Figure 7  Crude and age-standardised annual rates of severe S. pyogenes infection 
reports, Europe 2003-2004 
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Age-standardised rates of severe S. pyogenes infection reports varied substantially 
(Figure 8).  The overall rate for the eight countries was 2.37 per 100,000 population.  A 
general north-south pattern could be discerned among participants, with the four most 
northern European countries having the highest rates of reports, 2.58/100,000 in 
combination.  Within this group, rates in the UK (2.94) were significantly higher than 
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those for Finland or Sweden (2.28 for each; RR=0.78, 95% CI: 0.65-0.92) or Denmark 
(2.19; RR=0.74; 95% CI: 0.63-0.89).  Among the two central European countries, the 
highest rate was reported for the Czech Republic (1.48), with rates for Romania (0.36) 
more similar to those observed in Italy (0.40) and Cyprus (0.30). 
 
Figure 8  Annual age-standardised rates of severe S. pyogenes infection by 
country, Europe 2003-04 
 
Age-adjusted rates of severe S. pyogenes infection were plotted against data supplied 
by hospitals participating in the European Antimicrobial Resistance Surveillance Scheme 
on rates of blood culture sets according to estimated catchment populations.  Data were 
available for the following Strep-EURO/EARSS participants: Cyprus, Czech Republic, 
Finland, Italy, Romania, Sweden and the UK (Figure 9).  A strong positive correlation 
could be seen between country-specific rates of infection and rates of blood cultures 
sets examined (Spearman’s r = 0.92, p=0.003). 
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Figure 9  Correlation between country-specific rates of blood culture sets taken in 
2004 and rates of severe S. pyogenes infection in 2003-04 
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5.3. Age and sex-specific rates of infection 
Age and sex-specific rates of severe S. pyogenes infection were calculated for the Czech 
Republic, Denmark, Finland, Sweden and the UK and sex-specific rates only for Cyprus, 
Italy and Romania owing to the small numbers of cases reported.  In all countries bar 
Denmark, the rates of infection reports were higher in males than females (Figure 10), 
overall 3.03 vs 2.55 per 100,000 population (RR=1.19; 95% CI: 1.12-1.26).   
 
Rates of infection were highest in the elderly, and to a much lesser extent in young 
children (0-4 years old; Figure 10).  For Finland and the Czech Republic, the elevation in 
the elderly (75+ years) was much less pronounced than for the other countries (less than 
6/100,000 for both sexes), whereas in Sweden the reverse was true, with rates of 16 and 
13/100,000 in males and females respectively.  A slight elevation in women of child-
bearing age could also be discerned, most markedly in Denmark.  Data from the UK 
were unusual in showing a prominent elevation in young males (25-44 years old). 
 
 49 
Figure 10  Annual age-specific rates of severe S. pyogenes infection, 2003-04 
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5.4. Representativeness of cases with questionnaires returned 
Of the 5522 severe S. pyogenes cases identified, questionnaires were returned for 79% 
(4334 cases).  Comparison of variables available for cases with and without 
questionnaires returned identified those with questionnaires to be slightly older than 
cases without questionnaires (median age 53 vs 45; Kruskal-Wallis Test χ2(1 df)=7.24; 
p<0.01), although their sex distribution was similar (χ2(1 df)=1.11; p=0.29) as was peak 
season onset (January-March; (χ2(1 df)=3.07; p=0.08)).  Analysis of UK cases linked to the 
national deaths registry identified a significantly higher proportion of cases with 
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questionnaires returned to have died from any cause within seven days (18%) compared 
to cases without questionnaires (12%; (χ2(1 df)=19.34; p<0.001)). 
 
5.5. Clinical manifestations of S. pyogenes infection  
Clinical information was available for 3894 (71%) of cases in total (Table 8).  Of these, 
19% (631) had a disseminated infection with no focus of infection reported.  None of the 
cases from Romania and only 2 of 179 (1%) from Germany had a non-focal infection, 
whilst 10 to 26% of cases in other countries were reported as bacteraemic without focal 
symptoms.  Of the focal infections, cellulitis was the most commonly reported overall 
(32%) and for the majority of countries, with the exception of the Czech Republic, France 
and Italy where necrotizing fasciitis was more often identified.  Data on cellulitis were not 
collected from Sweden.  In total, 308 cases of necrotizing fasciitis were identified, 8% of 
all cases.  Necrotizing fasciitis was more common among male cases than female (9% 
vs 7%; χ2(1 df)=3.99; p=0.05), although not significantly so if injecting drug users (IDUs) 
are excluded (χ2(1 df)=2.45; p=0.12).  Other presentations reported included septic arthritis 
(9%), puerperal sepsis (3%) and meningitis (2%).  France reported relatively high 
numbers of puerperal sepsis cases, 9%, compared to other countries (5% or less).   
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5.6. Development of STSS  
Overall, 13% (493/3894) of cases developed STSS, rising to 50% among cases of 
necrotizing fasciitis.  Between 10 and 15% of patients with other clinical presentations 
developed STSS, aside from cases with non-focal infections, only 5% of whom 
developed STSS (Figure 11). 
 
Figure 11  Development of STSS according to clinical presentation, Europe 2003-04 
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Risk of STSS was highest among adults aged 16-60 years old (Table 9), 17% of whom 
developed STSS compared to 10% of paediatric or elderly cases.  Across all age 
groups, necrotizing fasciitis patients had the highest likelihood of STSS, reaching 55% in 
those aged 16-60.      
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Table 9  Risk of STSS according to clinical presentations and age, Europe 2003-04 
N=3733 children (<16y) adults (16-60y) adults (>60y) 
 no. with STSS (%) no. with STSS (%) no. with STSS (%) 
All cases 49 (10%) 277 (17%) 166 (10%) 
Bacteraemia with no defined focus 1 (1%) 14 (6%) 17 (6%) 
Necrotizing fasciitis 5 (29%) 100 (55%) 47 (44%) 
Cellulitis 3 (3%) 54 (13%) 45 (9%) 
Septic arthritis 4 (5%) 19 (12%) 11 (10%) 
Puerperal sepsis 0 (0%) 14 (13%) 0 (0%) 
Meningitis 2 (12%) 7 (24%) 0 (0%) 
 
Multivariable analysis was undertaken to identify microbiological, demographic, clinical 
and risk factors potentially associated with development of STSS.  Analyses were 
restricted to patients with sterile site isolates only to allow site of isolation to be 
examined as a possible predictor of STSS, given that the only patients with non-sterile 
site isolates included in the study were those with STSS.  These analyses identified 
younger adults (16-60y; OR=3.0) and the elderly (>60y; OR=1.4) to be at higher risk of 
STSS than children, as were patients with necrotizing fasciitis (OR=4.4), those with post-
surgical infections (OR=1.88) or patients infected with emm/M3 (OR=3.7) or emm/M1 
(OR=3.0) compared to emm/R28.  In contrast, injecting drug users (IDUs) were less 
likely to develop STSS (OR=0.2) than other patients, as were patients with cellulitis 
(OR=0.7) or those with non-focal infections (OR=0.4). 
 
 
5.7. Clinical data from the UK 
Within each country, considerable numbers of cases presented with conditions other 
than those detailed in Table 8, between 22 and 50% of cases per country.  Further 
exploration of data from the UK identified pneumonia as being the most common of 
these other presentations, identified in 12% of patients (Table 10).  Analysis of data from 
UK IDUs identified this group as being at particular risk of pneumonia (see 5.10 
Injecting drug users in the UK). 
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Table 10  Clinical presentations among cases of severe S. pyogenes infection, UK 
2003-04 
 
all cases* children (< 16y) adults (16-60y) adults (> 60y)   
no.  (%) no.  (%) no.  (%) no.  (%) 
Bacteraemia with no defined focus 558 (21%) 77 (24%) 228 (19%) 252 (24%) 
Skin/soft tissue infection 1099 (42%) 85 (27%) 479 (39%) 531 (50%) 
Cellulitis 881 (34%) 59 (19%) 362 (30%) 457 (43%) 
Necrotizing fasciitis 136 (5%) 4 (1%) 87 (7%) 45 (4%) 
Abscess 134 (5%) 6 (2%) 112 (9%) 16 (2%) 
Erysipelas 24 (1%) 2 (1%) 9 (1%) 13 (1%) 
Respiratory tract infection 434 (17%) 66 (21%) 187 (15%) 181 (17%) 
Pneumonia 309 (12%) 27 (8%) 139 (11%) 143 (13%) 
Other lower respiratory tract infection 62 (2%) 6 (2%) 26 (2%) 30 (3%) 
Pharyngitis/tonsillitis 51 (2%) 26 (8%) 16 (1%) 9 (1%) 
Ear infection 22 (1%) 8 (3%) 9 (1%) 5 (<1%) 
Epiglottitis 17 (1%) 2 (1%) 10 (1%) 5 (<1%) 
Sinusitis 6 (<1%) 4 (1%) 0 (0%) 2 (<1%) 
Septic arthritis 220 (8%) 40 (13%) 114 (9%) 66 (6%) 
Puerperal sepsis 58 (2%) 0 (0%) 58 (5%) 0 (0%) 
Acute abdomen† 49 (2%) 5 (2%) 31 (3%) 12 (1%) 
Cardiac infection‡ 48 (2%) 2 (1%) 36 (3%) 10 (1%) 
Meningitis 37 (1%) 18 (6%) 12 (1%) 7 (1%) 
 2611 (100%) 318 (100%) 1225 (100%) 1064 (100%) 
 
* Includes cases without age information.  
† Includes 14 patients with peritonitis, 1 with appendicitis, 1 with pancreatitis. 
‡ 42 patients with endocarditis, 4 patients with pericarditis, 1 with myocarditis, 1 with myocarditis & pericarditis.
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5.8. Factors predisposing severe S. pyogenes infection 
Information on risk factors was available for 3178 (58%) of the cases.  For 21% (683) of 
patients, no particular risk factors were identified, varying substantially between 
countries from 0% to 27% (Table 11).   
 
Table 11  Risk factors reported among cases of severe S. pyogenes infection by 
age, Europe 2003-04 
N=3176 children (<16y) adults (16-60y) adults (>60y) 
 
no. (%) no. (%) no. (%) 
Skin lesion/wound 
Immunocompromised 
Diabetes 
Injecting drug use 
Surgery 
Chickenpox 
65 (18%) 
7 (11%) 
0 (0%) 
1 (2%) 
0 (0%) 
7 (11%) 
284(22%) 
43 (15%) 
19 (7%) 
59 (21%) 
3 (1%) 
2 (1%) 
332 (32%) 
33 (10%) 
47 (14%) 
0 (0%) 
2 (1%) 
0 (0%) 
Immunocompromised 30 (8%) 226 (16%) 272 (20%) 
Injecting drug use 1 (<1%) 467 (32%) 3 (<1%) 
Diabetes 3 (1%) 66 (5%) 192 (14%) 
Chickenpox 73 (20%) 7 (1%) 2 (<1%) 
Hospital-acquired infection 
Prior surgery 
21 (5%) 
15 (71%) 
117 (8%) 
73 (62%) 
127 (9%) 
78 (61%) 
No identified risk factors 144 (37%) 241 (17%) 297 (22%) 
  388 (100%) 1440 (100%) 1348 (100%) 
 
The most common single risk factor reported across all age groups was skin lesion, 
reported in 25% of cases overall (681), rising to 32% among the elderly (Tables 11, 12); 
10% of these patients had diabetes (66) and 9% (60) were injecting drug users.  
Amongst children (<16 years old), chickenpox was the most common risk factor, 
reported in 20% (73) of cases overall.  In total, 471 (15%) cases were IDUs, 93% (440) 
of these from the UK where 22% of cases were IDUs compared to 6% or less in other 
countries.  Among young adults (16-60 years old), injecting drug use was the 
commonest risk factor, identified in 32% of cases.  
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Nearly half (45%; 21) of the cases from Greece were patients with chickenpox, a 
reflection of the largely paediatric setting of the surveillance in this country, all bar one of 
these 21 cases being children (Table 12).  Other notable differences between countries 
included the proportion of patients with diabetes in the Czech Republic (22%) and 
Sweden (14%).  This proportion remained high even among patients less than 75 years 
old, with 20% and 12% of Czech and Swedish cases respectively in this age group 
noted as having diabetes, compared to less than 6% in all other countries.  Eight per 
cent of cases (265) were associated with healthcare interventions, although higher in the 
Czech Republic and France, 26% and 17% respectively, with post-surgical infections 
accounting for most of these. 
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5.9. Ethnicity of patients from the UK 
Data collected on the UK cases included information on the ethnic group that patients 
belonged to.  Ethnicity was recorded for 48% (1822) of patients in total (69% of patients 
with questionnaires).  Of these 1822 cases, 95% (1727) were described as white, 3% 
(58) from the Indian subcontinent and 1% (21) black African or Caribbean.  Rates of 
severe S. pyogenes disease observed were significantly higher among whites (3.29) 
than those of Indian subcontinent (2.46; RR=1.34; 95% CI: 1.02-1.74) or black African or 
Caribbean origin (1.79; RR= 1.91; 95% CI: 1.16-2.75). 
 
5.10. Injecting drug users in the UK 
5.10.1. Geographical and temporal distribution of cases 
All countries within the UK reported cases of severe S. pyogenes infection in injecting 
drug users (IDUs) during 2003 and 2004, although IDUs constituted substantially higher 
proportions of all cases in England (21%) and Scotland (16%) than Wales (4%) or 
Northern Ireland (3%).  Within England, cases in IDUs were most highly concentrated in 
the north of the country, especially within the Yorkshire and the Humber region where 
44% of all cases were in IDUs in 2003-04, rising to nearly half (47%) of all cases in 2003 
(38% in 2004). The North West and East Midlands also had high concentrations of IDU 
cases, 32% in 2003, falling to 25% and 20% respectively in 2004.  The London region 
also reported relatively high numbers of IDU cases, 41% in 2003 falling to 20% in 2004.  
In contrast, the South West (17%), West Midlands (11%), North East (11%) and East of 
England (5%) all saw relatively fewer cases in IDUs over the two years.  Spatial and 
temporal analysis of cases in IDUs identified 30% (138) to form part of one or more IDU 
clusters, being diagnosed within 10km and 30 days of another case in an IDU.  A total of 
87 clusters were identified, with a median and mean size of 5 cases (max 13).  
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5.10.2. Clinical presentations in IDUs 
Of the 459 cases in IDUs, 96% (442) had positive blood cultures, higher than the 
proportion of non-IDUs (90%; χ2(1 df)=19.69; p<0.001).  Skin and soft-tissue isolates were 
cultured with similar frequency in both groups, 15% of IDUs and 17% of non-IDUs.  
Clinical information was given for all cases except three of the IDUs and two of the non-
IDUs.  A similar proportion of both groups had a disseminated infection without obvious 
clinical focus, 22% of IDUs and 20% of non-IDUs.  Of the focal sites for infection, skin 
and soft-tissue was the most common for both, although higher for non-IDUs (46%) than 
IDUs (37%).  Abscesses were substantially more common in IDUs (18%) than non-IDUs 
(2%).  Cardiac infections (endocarditis, myocarditis and pericarditis) were reported in 7% 
of IDUs, compared to 1% in other cases, with two-thirds (30/47) of all cardiac infections 
reported being in IDUs.  Deep vein thrombosis was similarly more common in IDUs, 6% 
vs <1% in non-IDUs.  
 
Respiratory tract infections were reported with similar frequency in IDUs and non-IDUs, 
although pneumonia was slightly more common in IDUs (14%) than other cases (11%), 
and twice as common in IDUs than non-IDUs of a similar age (15-44 years old, 7%; χ2(1 
df)=9.51; p=0.002).  Multivariable analysis of data from all UK cases indicated a three-fold 
increased likelihood of pneumonia in IDUs compared to non-IDUs (OR=3.00, 95% CI: 
1.63 to 5.51, p<0.001).  Other factors found to independently predict development of 
pneumonia were diagnosis in December (OR=2.04, 95% CI: 1.06 to 3.92, p=0.032) 
compared to a January baseline, and being aged 50-59 (OR=2.01, 95%CI=1.03 to 3.92, 
p=0.04) or 70-79 (OR=2.02, 95% CI: 1.09 to 3.77, p=0.026) compared to a 0-10 year old 
reference group. Patients infected with an emm/M83 strain (OR=0.38, 95% CI: 0.16 to 
0.89, p=0.027) were also found to have a significantly lower risk of pneumonia than 
patients infected with other emm/M-types, with emm/M83 identified in 16% of IDUs with 
pneumonia compared to 23% of IDUs with other clinical presentations.   
 
Comparison of clustered and non-clustered IDUs identified the latter to more commonly 
present with a respiratory tract infection, 18% vs 10%  (χ2(1 df)=4.71; p=0.03), in particular 
pneumonia, diagnosed in 17% of non-clustered cases compared to 8% of clustered 
IDUs (χ2(1 df)=5.68; p=0.017). 
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5.10.3. Microbiological characteristics of IDU isolates 
Corresponding isolates were received for 327 of the 459 IDUs (71%), and 1431 (77%) of 
non-IDUs.  A total of 44 emm/M-types were present among the 327 IDU isolates, 
compared to 61 among the 1431 non-IDU isolates.  Distribution of emm/M-types was 
markedly different between the two groups, most notably the high proportion of 
emm/M83 strains which constituted 22% of IDU infections and only 2% of non IDUs’ (χ2(1 
df)=186.07, p<0.001).  Seventy per cent of all infections caused by emm/M83 were in 
IDUs. The next most common type identified in IDUs was emm/M87 (11% vs 10% in 
non-IDUs), followed by emm/M82 (9% vs 1%), emm/M43 (6% vs 1%) and emm/M33 
(6% vs <1%).   The following types were only identified in IDUs: emm/M88 and 
emm/M94 (2 cases each) and 1 case each of the following - emm/M27, emm/M92, 
emm/M102, emm/M25, emmst4986.  The first and second most common types in non-
IDUs, emm/M1 and emm/M3, were relatively uncommon in IDUs (3% and 2% of isolates 
respectively).  
 
A greater diversity of emm/M-types was apparent among the 83 clustered IDUs with 
isolates available than the 244 non-clustered IDUs with isolates, with an average of 
three isolates per emm type for the clustered cases compared to six per type for the 
non-clustered cases.  emm/M44 (5% vs 1%; χ2(1 df)=5.50, p=0.02), emm/M68 (4% vs 0%; 
χ2(1 df)=8.90, p=0.003), emm/M81 (8% vs 2%; χ2(1 df)=5.79, p=0.016), emm/M93 (2% vs 
0%; χ2(1 df)=5.92, p=0.015) were over-represented among clusters, whereas emm/M89 
(0% vs 7%; χ2(1 df)=5.72, p=0.017) was under-represented.  Of the 87 individual IDU 
clusters, 67 (77%) had emm/M-typing results available from isolates from more than one 
member of the cluster.  Of these 67 clusters, only 3 involved a single type: one cluster of 
three emmstNS1033 cases (two isolates); two further clusters of two emm/M83 cases.  
 
 
5.11. Seasonal patterns of infection 
Seasonal patterns of infection were examined for all countries who collected more than 
250 cases over the two years: Denmark, Finland, France, Sweden and the UK.  All 
countries observed higher numbers of infections in the winter and spring period, and 
marked low levels during the summer and autumn.  March had the highest monthly 
excess of cases, 41% higher than the average monthly total.  Seasonal trends in Finland 
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were less pronounced than for other countries, however.  Striking similarities were 
observed in the timing of peaks and troughs between the five countries (Figure 12). 
 
Figure 12  Seasonal pattern of severe S. pyogenes infection by country 
 
5.12. Mortality following infection 
 
5.12.1. Case fatality rates according to clinical presentation 
Overall, 19% (643/3470) of patients died within seven days of diagnosis, with case 
fatality rates in the elderly substantially higher (32%) than children (9%) or younger 
adults (14%)(Table 13).  Case fatality rates were highest among cases of necrotizing 
fasciitis, 32% overall (80/254) and rising to 42% in the elderly.  Case fatality rates varied 
between countries, being highest for those reporting more cases of necrotizing fasciitis.  
Of the cases who developed STSS, 44% (184/415) died within seven days, with 31% 
(184/593) of all deaths being in patients with STSS.  Of the small number of cases with 
meningitis, 23% (12/52) died, and 17% (152/895) of cases with cellulitis.  Deaths in 
patients with septic arthritis (9%; 28/304) or puerperal sepsis (4%; 4/92) were less 
common.  Although risk of death was highest among patients with necrotizing fasciitis, 
the highest number of deaths were in patients with cellulitis who constituted 27% of all 
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the deaths reported (152/553), or 25% if the 14 cases also diagnosed with necrotizing 
fasciitis are excluded (138/553).  
 
Table 13  Seven-day case fatality rates according to clinical presentations and age 
among cases of severe S. pyogenes infection, Europe 2003-04 
N=3733 children (<16y) adults (16-60y) adults (>60y) 
 no. of deaths (%) no. of deaths (%) no. of deaths (%) 
All cases* 34 (9%) 178 (14%) 341 (32%) 
Bacteraemia with no defined focus 1 (1%) 25 (12%) 74 (33%) 
Necrotizing fasciitis 0 (0%) 41 (28%) 39 (42%) 
Cellulitis 3 (4%) 33 (9%) 116 (25%) 
Septic arthritis 1 (1%) 13 (10%) 14 (14%) 
Puerperal sepsis 0 (o%) 4 (4%) 0 (0%) 
Meningitis 4 (29%) 6 (24%) 2 (15%) 
* with clinical information reported 
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5.12.2. Case fatality rates according to risk factors 
Seven-day case fatality rates varied substantially according to underlying risk factors.  In 
children, younger adults and the elderly, those recorded as being immunocompromised 
for any reason had the highest fatality rates (Table 14), 17%, 20% and 32%.  Injecting 
drug users had a considerably lower risk of death (6%) compared to other cases within 
the same age band.  Of the cases without any predisposing factors, 9% and 10% of 
children and younger adults died with seven days, and 21% of the elderly cases.  
 
Table 14  Case fatality rates among cases of severe S. pyogenes infection by age 
and risk factor, Europe 2003-04 
N=2823 children (<16y) adults (16-60y) adults (>60y) 
 no. of deaths (%) no. of deaths (%) no. of deaths (%) 
 All cases* 34 (10%) 159 (13%) 315 (26%) 
Skin lesion/wound 2 (3%) 38 (15%) 91 (31%) 
Immunocompromised 5 (17%) 41 (20%) 76 (32%) 
Injecting drug use 0 (0%) 23 (6%) 0 (0%) 
Diabetes 0 (0%) 10 (19%) 49 (28%) 
Chickenpox 5 (8%) 0 (0%) 0 (0%) 
Hospital-acquired infection 2 (11%) 12 (11%) 29 (25%) 
No identified risk factors 11 (9%) 23 (10%) 57 (21%) 
 
* with risk factor information reported 
 
 
5.12.3. Independent predictors of poor survival 
Multivariable analyses were undertaken to evaluate the potential predictive value of the 
following factors on patient death: demographic variables (age, sex), month of diagnosis, 
clinical presentations, patient risk factors, antimicrobial susceptibility and emm type. 
Several factors were found to independently predict risk of death, as outlined in Table 
15, with the final model based on 1908 cases (the number of records with complete 
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information for all variables included in the model).  Age was the strongest predictor, with 
risk of death increasing steeply with increasing age.  Being immunocompromised was 
the only risk factor associated with risk of death, with these patients being 43% more 
likely to die within seven days than other patients.  Interestingly, patients diagnosed in 
October had a considerably reduced likelihood of death, 86% less than patients in 
January (reference month).  Of the main clinical presentations examined, several were 
found to carry a lower risk mortality compared to patients without these – non-focal 
infection, cellulitis, septic arthritis and puerperal sepsis.  Development of STSS was the 
only presentation found to significantly predict death, with these patients having 4 times 
the likelihood of death than others (necrotizing fasciitis did not significantly predict 
death).   
 
emm/M-types responsible for 30 or more infections were examined in the model.  Three 
emm types were dropped by the model due to low numbers resulting in complete 
prediction of failure in the model (emm/M2, 73 and 118).  Several emm/M-types were 
found to significantly predict death compared to the baseline comparator (emm/R28).  
The strongest association was for emm/M78 which was associated with over 3.5 times 
the risk of death, followed by emm/M5, emm/M3 and emm/M1.  As a common type, the 
highest number of deaths were associated with emm/M1 infection (30%; 175/587). 
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Table 15  Factors independently associated with mortality within seven days of 
severe S. pyogenes infection, 2003-04 
 no. cases (% died) adjusted OR 95% C.I. p value 
Patient characteristics     
Age group (years)      
< 1 82 (15%) 1 - - 
1-15  381 (9%) 2.19 (0.48 - 9.96) 0.312 
16-30 368 (5%) 1.71 (0.35 - 8.22) 0.505 
31-45 679 (13%) 3.38 (0.77 - 14.82) 0.106 
46-60 484 (18%) 5.09 (1.16 - 22.32) 0.031 
61-75 676 (25%) 8.04 (1.86 - 34.77) 0.005 
over 75 798 (30%) 13.87 (3.22 - 59.75) <0.001 
      
Immunocompromise 479 (25%) 1.43 (1.05 - 1.96) 0.022 
      
Month of diagnosis     
January 386 (23%) 1 - - 
February 347 (20%) 1.01 (0.60 - 1.68) 0.976 
March 427 (20%) 0.91 (0.56 - 1.48) 0.711 
April 413 (22%) 0.88 (0.54 - 1.43) 0.605 
May 288 (18%) 0.93 (0.54 - 1.61) 0.793 
June 257 (16%) 1.10 (0.61 - 1.99) 0.744 
July 282 (17%) 0.88 (0.51 - 1.52) 0.640 
August 197 (17%) 1.33 (0.71 - 2.48) 0.375 
September 181 (12%) 0.61 (0.30 - 1.27) 0.188 
October 190 (8%) 0.13 (0.04 - 0.44) 0.001 
November 216 (16%) 0.86 (0.45 - 1.66) 0.660 
December 286 (23%) 1.29 (0.75 - 2.25) 0.358 
      
Clinical features      
Cellulitis 895 (17%) 0.50 (0.37 - 0.66) <0.001 
Septic arthritis 304 (9%) 0.36 (0.20 - 0.64) 0.001 
Puerperal sepsis 92 (4%) 0.29 (0.08 - 1.04) 0.058† 
Non-focal bacteraemia 506 (20%) 0.66 (0.46 - 0.94) 0.022 
STSS 415 (44%) 4.03 (2.93 - 5.54) <0.001 
      
emm/M-type*     
emm/M28 351 (14%) 1 - - 
emm/M11 31 (10%) 0.55 (0.07 - 4.49) 0.575 
emm/M12 176 (17%) 0.99 (0.49 - 1.98) 0.974 
emm/M18 43 (21%) 1.16 (0.41 - 3.24) 0.783 
emm/M22 51 (12%) 0.58 (0.15 - 2.25) 0.431 
emm/M3 305 (36%) 2.37 (1.43 - 3.94) 0.001 
emm/M33 23 (4%) 0.16 (0.02 - 1.32) 0.089 
emm/M4 146 (10%) 0.66 (0.29 - 1.51) 0.328 
emm/M43 29 (21%) 1.87 (0.65 - 5.44) 0.248 
emm/M5 71 (30%) 2.73 (1.30 - 5.72) 0.008 
emm/M6 63 (17%) 1.08 (0.44 - 2.66) 0.865 
emm/M75 45 (9%) 0.71 (0.15 - 3.39) 0.668 
emm/M77 72 (21%) 2.12 (0.86 - 5.21) 0.103 
emm/M78 29 (28%) 3.36 (1.16 - 9.76) 0.026 
emm/M81 112 (10%) 0.62 (0.19 - 2.02) 0.428 
emm/M82 34 (9%) 0.96 (0.26 - 3.60) 0.956 
emm/M83 90 (8%) 0.77 (0.27 - 2.15) 0.615 
emm/M87 187 (19%) 1.10 (0.60 - 2.04) 0.754 
emm/M89 247 (13%) 0.69 (0.36 - 1.33) 0.268 
emm/M1 596 (29%) 1.67 (1.05 - 2.68) 0.032 
other 295 (11%) 0.48 (0.24 - 0.96) 0.037 
* emm/M types with 30+ isolates; - reference group; † Likelihood Ratio Test p-value = 0.0318 
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5.12.4. Reporting of case fatality 
Between countries, there was a general tendency towards higher case fatality rates 
being associated with less complete reporting of outcome (Figure 13; linear regression 
analysis R2=0.82, p<0.001); cases from Germany had a particularly high mortality, 40%, 
although this information was only provided for 42 (21%) of their 179 cases.  Conversely, 
cases from Finland and Sweden had a much lower mortality of 5% and 9%, with this 
information provided for 100% (in 2004) and 80% of their cases respectively.   
 
Figure 13  Correlation between completeness of mortality information and case 
fatality rate reported, Europe 2003-04 
 
Information on patient outcome for UK cases was available both through questionnaire 
reporting and through death registration records, with the latter identifying 16% 
(559/3422) of cases to have died within seven days of diagnosis (all cause mortality) 
compared to 21% (469/2237) of questionnaire responses (χ2(1 df)=19.51, p<0.001).  Of 
the 469 deaths identified through the questionnaire, the cause was not known for 45 
patients and 11 were noted as being due to other causes, leaving 413 (19%) deaths 
attributable to S. pyogenes infection.   
 
For 2062 cases, information on seven day mortality was available through both the 
questionnaire and through linkage to the national deaths registry.  Of these 2062 
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patients, the outcome at seven days was congruent between the two sources for 97% 
(2000/2065).  Forty-six deaths identified through the study questionnaire were not 
substantiated by the deaths registry, although 20 of these 46 had died between 8 and 30 
days after the initial positive culture.  Of 1633 patients noted as being alive through the 
questionnaire, 19 were identified as having died within seven days through the deaths 
registry.  The sensitivity of the questionnaire in identifying deaths within seven days was 
95% (386/405) and the positive predictive value 89% (386/432). 
 
5.13. emm/M-type distribution in the UK 
Of the 3775 cases of severe S. pyogenes infection identified in 2003-04, isolates were 
available for 2493 (66%).  Of these isolates, emm type was determinable for 2490 
isolates using one of a number of techniques (see 4.3.2 Collection and 
characterisation of isolates).  Comparison of information available for cases with and 
without accompanying isolates identified a higher likelihood of those with isolates to 
have subsequently died, as identified through the national deaths registry (11% vs 19%; 
χ2(1 df)=32.93, p<0.001). 
 
A total of 75 different emm/M-types were identified, including eight provisional types 
(emmst11014, emmst1389.1, emmst4986, emmstD633, emmstG1750, emmstNS1033, 
st2037.1, stG6).  The top 20 most common emm-types are given in Figure 14.  Overall, 
emm/M1 was the most common type, identified in 18% of isolates, followed by emm/M3 
(13%), emm/M87 (10%) and emm/M89 (8%). 
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Figure 14  Distribution of emm/M-types causing severe S. pyogenes disease, UK 
2003-04 
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Of the cases with non-focal bacteraemia, emm/M87 was overrepresented, accounting 
for 14% of these cases compared with 10% of cases overall (χ2(1 df)=3.79, p=0.05). No 
associations could be discerned between emm/M-type and skin and soft tissue 
infections as a whole, although among cases diagnosed with necrotizing fasciitis, 
emm/M1 (33%; χ2(1 df)=14.33, p<0.001) and emm/M3 (22%; χ2(1 df)=8.38, p=0.004) were 
overrepresented, whilst emm/M87 (2%; χ2(1 df)=8.19, p=0.004) was underrepresented 
(Table 16).  Both emm/M87 and emm/M28 were associated with puerperal sepsis, each 
identified in 22% (χ2(1 df)=5.99, p=0.017) and 17% (χ2(1 df)=8.04, p=0.005) of cases 
respectively.  No significant (single variable) associations were found between emm/M 
types and development of pneumonia (see 5.10.2 Clinical presentations of IDUs for 
results from multivariable analysis of factors associated with pneumonia).  Among cases 
who died within seven days of infection (Figure 15), emm/M1 (27% of deaths) and 
emm/M3 (23% of deaths) were overrepresented.  Conversely, emm/M83 (2% of deaths) 
was underrepresented among fatalities.   
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Figure 15  Distribution of emm/M-types* causing severe S. pyogenes disease 
according to seven-day case fatality†, UK 2003-04 
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* top 20 ranking emm/M-types; † within 7 days (patients may have died subsequently) 
 
5.14. Susceptibility of UK isolates to antimicrobial agents 
Antimicrobial susceptibility results were available for 2605 (69%) of UK cases.  Of these, 
4% of isolates were reported as erythromycin resistant, 15% tetracycline resistant and 
2% clindamycin resistant.  Of the erythromycin sensitive isolates, 1% were reported as 
clindamycin resistant, compared to 18% of the erythromycin resistant isolates (χ2(1 
df)=65.63; p<0.001). 
 
Resistance to erythromycin was also associated with tetracycline resistance, with 43% of 
erythromycin resistant isolates resistant to tetracycline compared to 14% of erythromycin 
sensitive isolates (χ2(1 df)=38.27; p<0.001). 
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Prevalence of erythromycin resistance fluctuated between 2 and 5% throughout the 
year, with no clear seasonal pattern.  Resistance varied by age (χ2(1 df)=10.29; p=0.006), 
with cases in children having the lowest rates of erythromycin resistance (1%), 
compared to adults aged 16-60 (3%) or the elderly (5%).  Infections associated with 
healthcare interventions also had a higher rate of erythromycin resistance (8% vs 4%; 
χ2(1 df)=3.64; p=0.06). 
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6. DISCUSSION 
 
The aim of this study was to define the epidemiology of severe S. pyogenes infection in 
Europe in 2003-04, with a special emphasis on the UK.  Analysis and interpretation of 
data collected would be of value to individual countries in assessing their burden of 
infection and evaluating the importance of different risk groups.  Pooling of data across 
nations would further allow an analytical evaluation of important factors predicting patient 
outcome.  The main findings and limitations of this work are discussed below. 
 
 
6.1. Interpretation of findings from the study 
6.1.1. Rates of infection across Europe 
Estimation of the incidence of severe S. pyogenes infection during this project identified 
a general north-south gradient, from high to low (II).  Remarkably similar age-
standardised rates of reports were observed among the three Nordic participants – 
Finland, Denmark and Sweden – between 2.2 and 2.3 per 100,000 population.  Rates in 
the UK were higher still, 2.9 per 100,000 or 3.3 if unadjusted, closer to the rates 
observed in the USA and Australia during this period[2;200;201].  The large number of 
cases in injecting drug users (IDUs) in the UK, 21% of all the UK’s cases compared to 
6% or less in other countries, are likely to have elevated this rate.   
 
In contrast, the rates of reports observed in the more central and southern countries – 
the Czech Republic, Romania and Italy – were substantially lower, 0.4 to 1.5 per 
100,000 population.  Although these lower rates might reflect a true lower incidence of 
infection, they are more conceivably explained by a poorer uptake of microbiological 
investigative methods within these countries, further substantiated by the strong 
correlation with rates of blood culture sets taken among participants in EARSS[107].  
Failure to report diagnosed cases could also account for the lower rates observed in 
some countries; evidence to support this assertion would be difficult to find. 
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6.1.2. Predictors of death 
One in five of cases identified during the study was reported to have died within seven 
days of infection (II).  This figure, like most estimates from the study, is highly influenced 
by the large body of data from the UK.  As such, it should be interpreted with particular 
caution given that survival data from the UK pooled with the other countries were 
obtained from the study questionnaire, rather than from any external and objective 
source.  The outcomes of cases of whose fate was unknown are probably less likely to 
have died, resulting in an overinflation of this estimate to some degree.  This is 
supported by the (inverse) correlation between completion of these data and case 
fatality rate between countries, along with the subsequent analysis of UK deaths registry 
data which identified a lower proportion of patients to have died (16%) than identified 
from the questionnaire alone (21%)(IV).  However, this overall case fatality rate does lie 
within the range observed in other studies[2-8]. 
 
Several factors were identified as being associated with increased risk of death.  Many 
have been identified by other studies, such as age, immune status, development of 
STSS and emm/M-type[1;4;11;117].  Despite its reputation, necrotizing fasciitis was not 
itself associated with increased risk of death, the high mortality in these patients being 
accounted for by the higher frequency of STSS, also found elsewhere[6].  Analysis of 
survival time in UK patients diagnosed with STSS illustrated the rapid deterioration of 
these patients, just over a quarter of whom died within a day of culture positive specimen 
collection.  Whether STSS should be considered as an event independent of death is 
possibly questionable, as its constituent clinical markers effectively denote the 
progressive shutdown of major organ systems, along with DIC and development of an 
erythematous rash, and as such would seem to signal the start of the process of death.   
 
Several studies have found pneumonia to be associated with increased risk of death, and 
whilst this presentation was not included in the European questionnaire(II), its inclusion in 
the UK questionnaire supports this finding(I).  Our study also found two serotypes - 
emm/M78 and emm/M5 – to be independently associated with an even higher risk of 
death than emm/M3 and emm/M1, a finding which was potentially only discoverable with a 
sample size as large as this given the relative infrequency of these types as a cause of 
invasive disease.  One further association was found which has not previously been 
documented, that mortality changes in parallel with season, with the highest case fatality 
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rates in peak season and the lowest in low season.  The risk of death in patients infected 
in October was nearly 90% less than in patients diagnosed in January.   
 
Whilst the findings above are of importance in identifying patients at higher risk of death, 
from a public health perspective, it’s essential to also evaluate factors associated with 
high numbers of deaths (mortality, rather than case fatality).  Whilst development of 
STSS was associated with a high risk of death, less than a third of deaths were in 
patients with STSS.  Although often overlooked given its frequency and usually 
uncomplicated outcome, more deaths were associated with cellulitis than any other 
clinical syndrome. 
 
6.1.3. Predictors of STSS 
Analysis of factors associated with STSS amongst the European cases supported 
previously identified associations, namely heightened risk in young adults compared with 
children or the elderly, patients with necrotizing fasciitis and patients infected with 
emm/M3[6;117;119].  Injecting drug users were found to have a lower risk of STSS than 
other patients, a finding not reported elsewhere, as were patients with malignancies.  
Further analyses were undertaken with the more detailed UK data(I), which found 
alcoholism to be associated with increased risk of STSS, also found by others[4;7]. 
However, we found that patients recorded as having used non-steroidal anti-
inflammatory drugs had three times the likelihood of developing STSS, despite 
adjustment for whether the patients had necrotizing fasciitis, itself strongly associated 
with STSS.  As no data were collected specifying the timing, dose, indications for use or 
which agent was taken, one cannot infer a causal link between use of non-steroidal anti-
inflammatory drugs and development of STSS from our findings.  A confounding factor, 
such as delay in receiving appropriate treatment, not adjusted for in our analysis could 
explain the finding.  It is also possible that patients who took non-steroidal anti-
inflammatory drugs had early signs indicating a more severe infection, such as extreme 
pain.  Nonetheless this remains an interesting and potentially important observation in a 
controversial area where evidence supporting either immunological impairment or 
augmentation due to non-steroidal anti-inflammatory drugs remains unresolved at 
present[144].   
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6.1.4. Seasonal patterns of infection 
The similarities in the seasonal patterns of infection in different countries observed in this 
study are among the most striking of the results(II).  The near simultaneous changes are 
difficult to explain as they point to an influence whose timing of effect would be very 
similar between countries.  A climatic explanation would seem plausible, for example a 
change in humidity affecting mucosal defence, which could in turn also explain the east-
west axis of low to high incidence in Canada, given the relatively dry and arid conditions 
in the west.  Daily photoperiod is known to influence immunological defence, given that 
both vitamin D and melatonin production are affected by this cycle[146;202].  
Interestingly, serum levels of vitamin D (25(OH)D3) are known to be lower in individuals 
with darkly pigmented skin[203], which could offer an explanation for the increased 
incidence reported in various non-white ethnic groups, although not found in the UK.  
Although the evidence for the importance of photoperiod on the winter excess of deaths 
is fairly compelling, and in particular deaths associated with influenza, the pattern of 
incidence for S. pyogenes infections does not follow a mid-summer low mid-winter high 
cycle[146;165].  Seasonal changes in behavioural patterns, either as a result of external 
temperature affecting indoor gathering versus outdoor pursuits or dictated by the 
academic calendar are likely to influence the chains of transmission.  The long summer 
holidays may disrupt transmission, in particular among children, an important reservoir 
for many infectious diseases, although one might again expect the summer months to 
see the lowest incidence in this case.  That the risk of death also changed with the 
season in parallel with the incidence of infection, is a novel and fascinating finding, which 
would fit with an immunological theory.  Clearly some residual and unaccounted for 
factor influencing immunological function and connected to time of year is exerting an 
important effect.   
 
6.1.5. Factors predisposing to infection 
Analysis of factors potentially predisposing to severe S. pyogenes infection found that 
that a quarter to a fifth of cases in most countries had no particular factors predisposing 
to severe infection, based on responses made in the study questionnaire(II).  A certain 
degree of caution should be exercised in interpreting these results as it was left to the 
discretion of the reporting clinicians (or country co-ordinators in further cleaning data) as 
to what might be considered a risk factor beyond the standard options given on the study 
questionnaire.  In some countries, for example Sweden, coronary heart disease was 
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included within this list, a condition of sufficient commonality in the elderly that this could 
have some influence on the estimation of numbers of patients without risk factors.  Of 
the patients without apparent risk factors, there may of course have been events or 
exposures which predisposed to infection which would not have been readily 
considered, such as presence of an intrauterine device[155].  Furthermore, it would be 
easy to overly infer that any risk factors which were mentioned were of relevance to the 
development of infection in any given patient.  Many accepted ‘risk factors’ have no 
epidemiological evidence as their basis. 
 
This limitation notwithstanding, some interesting findings emerged, the most striking of 
which was the high proportion of IDUs among UK cases (22%) compared to any other 
country (≤ 6%), discussed further below.  Two countries reported substantially higher 
proportions of their cases being healthcare intervention related, the Czech Republic 
(26%) and France (17%), most other countries reporting approximately 10% of cases as 
being healthcare associated.  Several maternity clusters occurred in France during this 
period, probably accounting for their figure, although it remains unclear why the 
proportion in the Czech Republic should be so high.  A further notable difference 
between countries lies in the high proportion of cases from the Czech Republic (22%), 
and to a lesser extent Sweden (14%), having diabetes.  The prevalence of diabetes in 
the general population is known to be high in the Czech Republic, possibly explaining 
their figure, although it remains unclear why the Swedish cases should be so 
different[204]. 
 
6.1.6. Upsurge of cases in UK drug injectors 
Analysis of the wealth of information collected on cases of severe S. pyogenes infection in 
UK injectors indicates that a distinct epidemic occurred in this group in the UK(III), peaking 
in 2003[205].  Serotypes involved in causing disease in injectors were markedly different 
to those in non-injectors, with several serotypes only seen in injectors.  These cases are 
clinically interesting – 14% of cases presented with pneumonia, indicating that non-
injecting routes of infection were important in fuelling this epidemic.  Multivariable analysis 
of data from all cases indicated a three-fold increased likelihood of pneumonia in IDUs 
compared to non-IDUs when adjusting for age, season and emm/M-type.  Although single 
variable analysis suggested that IDUs were less likely to die than other cases, 
multivariable analysis failed to find any difference between IDUs and others, suggesting 
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that their better outcome is explained by the reduced likelihood of developing STSS and 
by the serotypes involved in their infection.  That IDUs were less likely to develop STSS 
may relate to a greater natural immunity in IDUs through repeated infection with S. 
pyogenes over time, rendering IDUs more immunologically primed to respond to such 
infections and less susceptible to the common strains infecting non-IDUs. 
 
The IDU cases seemed to be divided into two broad categories: clustered cases, 
infected with a diverse range of serotypes, presenting with range of clinical 
manifestations and more likely to be admitted from an institution; non-clustered cases, 
presenting with a range of infections but with more lower respiratory tract infection than 
clustered cases and infected with a narrower range of serotypes.  These findings 
suggest that the clusters may be occurring in more marginalised injectors as a result of 
injecting behaviour, whereas the non-clustered cases are possibly infected through 
respiratory transmission.   
 
The drivers behind this increase in injectors are not understood, although it is of interest 
to note that a similar increase was seen in Barcelona in 2003[206].  Increases in cocaine 
injection were considered to have led to an upsurge of severe S. pyogenes infection 
seen in IDUs in Philadelphia between 1979-89[207], injection of cocaine facilitating 
tissue necrosis through localised vasoconstriction.  This could explain the rise seen in 
the UK, with anecdotal evidence indicating the adoption of a new marketing strategy by 
UK drug dealers during the 2000s to increase demand for crack-cocaine – provision of 
free crack ‘rocks’ with heroin purchases, allowing the two drugs to be dissolved and 
injected together (“speedballing”).  An increase in cocaine injecting, would also explain 
the rise in outbreaks of anaerobic infections seen in the UK in the early 2000s[208-210].   
 
6.1.7. Potential impact of vaccine candidates 
The collection of around 2500 isolates involved in severe S. pyogenes infection in the 
UK permits an evaluation of the potential impact of multivalent vaccine candidates, in 
particular the two currently under trial.  Assuming 100% efficacy, the hexavalent vaccine 
candidate could have potentially prevented 36% of the cases identified in 2003-04 and 
56% of the associated deaths occurring within seven days[184].  In contrast, the 26-
valent vaccine could have prevented 67% of cases (and 80% of deaths)[185], lower than 
recent estimates for Canada (72%), the USA (79%), Japan (82%) or Mexico (86%) 
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[1;94;98;211] but above the 22% recently reported in Hawaii[212].  Setting aside 
efficacy, any estimates of impact may be undermined by the potential for serotype 
replacement to occur subsequent to initiation of an immunisation strategy[213], which 
given the current experience with pneumococcal vaccination and suggested in at least 
one GAS carriage study[214], may well represent a real threat[215].  A range of different 
emm/M-types are involved in invasive disease, 75 in this analysis in the UK, outlining the 
pathogenic potential of less common types.  Furthermore, this species is clearly still 
evolving, with novel types continuing to emerge, potentially further undermining any 
vaccine targeting the M-protein.   
 
 
6.2. Methodological considerations 
As with any scientific endeavour, a number of limitations are inherent to this work and as 
such certain considerations should be held in interpreting the data.  The interpretation of 
the results discussed in 6.1 Interpretation of findings from the study are made taking 
these into account, and in turn these are reflected in 6.3 Future considerations.  The 
main limitations and caveats are outlined below. 
 
6.2.1. Design limitations 
The main limitation of a surveillance study is the inability to make robust comparisons 
between cases and an external or control group of individuals.  Although it is possible to 
compare the characteristics of cases to normative data collected at the population level 
as undertaken in some studies, this would be limited to factors for which normative data 
exist.  Furthermore, as such data are collected using entirely different methodology, 
there exists the potential for making an invalid comparison.   
 
Given these limitations, it is not possible to make any inferences on the importance of 
specific risks as one cannot measure the strength of association for which a control 
group is required.  As some of the risk factors for severe S. pyogenes infection are 
reasonably common, such as cardiovascular disease, comparison of the frequency of 
this condition in cases has to be compared to a control group if it’s to have any meaning.  
Nonetheless, the descriptive epidemiology of possible predisposing factors provided by 
surveillance studies is still of value in directing further research as well directing public 
health activity where clear excesses arise in particular subgroups. 
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6.2.2. Surveillance methods 
One of the most important limitations of this work are the methodological differences 
between countries in collection of cases(II).  This prevented estimation of rates of 
infection for three of the eleven participating countries, primarily owing to a lack of 
participation by hospitals in these countries.  Under such circumstances, further 
concerns arise that biases may be introduced in the cases which are reported.  Cases 
reported may be ones that were of particular interest owing to some novel feature, 
responded poorly to treatment or were particularly severe.  Some evidence for the latter 
can be found from the Czech Republic, France, and Italy, all of whom reported one in 
five of their cases as having necrotizing fasciitis, suggestive of a possible bias either in 
the application of microbiological investigation or in the reporting of more severe cases.   
 
Although less problematic than the above, two countries did not adopt the standardised 
surveillance questionnaire agreed by the project owing to ongoing surveillance activity.  
For one of these, Denmark, this would probably have had little effect as their 
questionnaire covered the items included in the Strep-EURO questionnaire.  However 
for Sweden, their questionnaire did not capture the same range of clinical presentations.  
As such, no estimates for cellulitis could be made, nor for non-focal bacteraemia.  As the 
second largest contributor to the programme, this represents a missed opportunity. 
 
 
6.2.3. Participation rate 
Inherent to questionnaire-based research is the potential for biased completion of 
questionnaires.  Comparison of data available for European cases with and without 
questionnaires did not point to any differences in a number of factors(II), although cases 
with questionnaires were slightly older than others (median age 53 vs 45).  However, a 
number of countries only identified cases through questionnaire completion or other 
active means (isolate referral), and as such comparative data do not exist for them.  
Furthermore, the factors that one would most like to have available for comparison, 
namely clinical presentations, risk factors and mortality, are the very ones usually not 
available for comparison.  Within the UK, linkage of records for all cases to the national 
register of deaths provided an opportunity to examine a potential bias in questionnaire 
return or isolate referral(IV), and indeed found that cases for whom questionnaires were 
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completed or isolates submitted had a higher mortality than those without questionnaires 
or isolates.  Although the same calculations cannot be made for other countries, it is 
likely that there could be biases present within their data collection, further supported by 
the observed correlation between case fatality rates and completion of outcome 
information and the varying severity of clinical presentations between countries. 
 
6.2.4. Data collected 
Studies on the scale of the one undertaken here will necessarily be limited in the number 
of data items collected.  The choice of items included on a study questionnaire or 
microbiological analyses undertaken fundamentally shapes our ability to draw novel 
conclusions from any research – what is not looked for cannot be found.  Multinational 
research projects are potentially even more prone to limiting themselves as to what they 
look for in that one person’s hypothesis or experience is unlikely to convince a multitude 
of collaborators. 
 
Although the study questionnaire devised for this project struck a reasonable balance 
between comprehensiveness and brevity, some key items ought to have been included.  
The clinical presentations listed should have included pneumonia and acute abdominal 
presentations given their frequency.  Capture of data on treatment strategies would have 
also been valuable in assessing different approaches in different countries, in particular 
in the use of IVIG. 
 
Owing to financial constraints, use of subtyping techniques in analysing isolates 
captured was rather limited, as was the identification of virulence markers, such as spe 
genes.  The latter represents a missed opportunity as analysing the association between 
these and different clinical presentations and outcomes would have been of 
considerable value.  However, all isolates have been archived, and as such these 
analyses could be undertaken in the future. 
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study re-emphasise the dynamic nature of these infections and the need for 
constant vigilance to detect new and emerging patterns of disease; 
2. Development of algorithms to routinely assess case fatality rates and absolute 
mortality to detect exceedances above those seasonally expected should be 
considered; 
3. Comparison of seasonal patterns of infection from countries in different 
continents, along with correlations to environmental and social parameters, could 
yield some interesting insights into this interesting phenomenon; 
4. A case-control study should be undertaken to evaluate the role of non-steroidal 
anti-inflammatory drugs as a potential risk factor for development of STSS; 
5. An evaluation of the long term sequelae of severe S. pyogenes infection should 
be considered as a means of evaluating the burden of infection; 
6. A detailed investigation of cases of severe S. pyogenes infection with no 
apparent risk factor or portal of entry should be undertaken to generate 
hypotheses on novel factors to be tested in analytical studies; 
7. Guidelines should be developed on the investigation and management of 
clusters of severe S. pyogenes infection occurring in maternity settings; 
8. The utility of primary care surveillance systems in forecasting epidemic rises in 
severe S. pyogenes infections should be assessed. 
 
 
 
6.3. Future considerations 
1. Continuation of surveillance of severe S. pyogenes infection to monitor changes 
in rates of infection, risk factors, clinical presentations, emm/M-type distribution 
and antimicrobial susceptibility patterns remains essential.  Results from this 
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7. SUMMARY AND CONCLUSIONS 
 
7.1. Key findings from the study 
In accordance with the original study objectives, the following findings were made. 
 
To measure and compare the overall and disease-specific burden of S. pyogenes 
disease in eleven countries across Europe 
· In northern European countries, between 2 and 3 individuals per 100,000 
population succumb to a severe Streptococcus pyogenes infection per year; 
· Rates of severe S. pyogenes infection in central and southern European 
countries were lower, a probable reflection of the poorer application of 
microbiological diagnostic techniques in hospitals; 
· Seasonal patterns of infection were very similar between countries, with near 
simultaneous timing in certain up- and downswings. 
 
To identify and compare key risk groups in each country to potentially identify targets for 
public health intervention 
· Males were at higher risk of infection than females, as were the elderly; 
· The age distribution of patients in Finland was unusual in having low rates in the 
elderly;  
· IDUs constituted a substantially higher proportion of cases in the UK than any 
other country, 40% of cases in adults aged 16-60y. 
 
To identify factors associated with development of STSS as a means of directing future 
basic research into disease pathogenesis 
· Development of STSS was highest in young adults, patients with necrotizing 
fasciitis, patients with post-surgical infections and patients infected with emm/M3 
and emm/M1; 
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· Patients with cellulitis, patients with non-focal infections and injecting drug users 
were at lowest risk of STSS; 
· Analysis of UK data found use of NSAIDs to be significantly associated with 
development of STSS. 
 
To undertake an in-depth analysis of cases occurring in UK injecting drug users 
according to emm types, clustering, clinical presentations and outcome to better 
understand the possible modes of transmission and burden of disease in this group 
· Clinical presentations in UK injectors were broadly similar to non-injectors, 
although drug injectors were more likely to present with pneumonia than other 
cases of the same age; 
· emm/M-types in UK injectors were distinct from other cases arising during the 
same period, with a strong predominance of emm/M83; 
· Temporal, spatial and microbiological analysis of data on cases in injectors 
suggests a distinct epidemic of infection occurred in the UK, peaking in 2003. 
 
To better understand clinical, demographic, microbiological and other possible predictors 
of mortality 
· Elderly patients, those with compromised immune systems, those who developed 
STSS and those infected with an emm/M78, emm/M5, emm/M3 and emm/M1 
were most likely to die as a result of their infection; 
· Non-focal infection, cellulitis, septic arthritis and puerperal sepsis were 
associated with low risk of death, as were infections occurring during the lowest 
season, October. 
 
Analysis of data gathered in the eleven countries participating in the Strep-EURO 
programme has yielded invaluable new information on the epidemiology of severe 
Streptococcus pyogenes infections in Europe during the 2000s.  The project succeeded 
in establishing the first European surveillance network for severe S. pyogenes infections, 
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through which over 5000 cases were identified over the two years, with a wealth of 
clinical and microbiological information accompanying the majority.   
 
Analysis of project data has brought some new insights into risk factors for severe S. 
pyogenes infection, especially the importance of injecting drug use in the UK, with 
infections in this group fundamentally reshaping the epidemiology of these infections in 
the UK.  Several novel findings arose through this work, namely the associations 
between NSAID and STSS, the high degree of congruence in seasonal patterns 
between countries, and the seasonal changes in case fatality rates.  Analysis of data to 
identify household clusters in the UK has doubled the number of household clusters 
identified worldwide as part of a coherent surveillance activity.  This has in turn allowed 
an evaluation of risk to contacts, forming the basis of guidance on the management of 
cases of S. pyogenes infection arising in the community.   
 
Surveillance of invasive infections caused by S. pyogenes is of considerable public 
health importance as a means of identifying long and short-term trends in incidence, 
allowing the need for, or impact of, public health measures to be evaluated.  By their 
very nature, S. pyogenes infections are dynamic, with changes in epidemiological 
patterns occurring frequently.  Monitoring the prevalence of circulating emm/M-types 
provides an early warning of likely increases in incidence of severe infection, as well as 
providing a means to evaluate the likely impact of multivalent vaccines currently under 
development. 
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10. ANNEXES  
10.1. UK Strep-EURO questionnaire 
      
E N H A N C E D  S U R V E I L L A N C E  O F   
S E V E R E  G R O U P  A  
S T R E P T O C O C C A L  I N F E C T I O N
 
              European Commission DG RTD QLK2.CT.2002.01398 
 Health Protection Agency use only 
strep-EURO ID  GB                received 
 
RSIL ref no: 0.…/….………../SA Name of laboratory…………………………………………………………………………………………………………………….….………. 
Your lab/hosp no……………………….. Isolate referred from (hospital & clinician name)... ……………………….……………………….…………………………………………. 
Address……………………………………………………………………………………………………………………………………………………………………………………………………... 
 IN STRICT CONFIDENCE                            Please tick boxes or write in the space(s) provided (see notes overleaf)  
 
COMPLETED BY:…………..……………………………………
TELEPHONE NO.: ………………………………………..
TODAY'S DATE: .……/..……/………………..
ii) ISOLATE DETAILS     
·Date of specimen (dd/mm/yyyy  
·Isolated from:  blood        1      joint          2     wound         3      CSF        4    
    other (please specify) 
·Other relevant pathogens associated with this illness/episode?     
    yes       1 (please specify) 
    no    2   not known          9 
i) PATIENT DETAILS 
·patient’s initials                    SOUNDEX 
·date of birth (dd/mm/yyyy) 
   or age            years/months/days (please delete)       not known        999 
·male 1   female       2    not known         9 
·date of hospital admission (dd/mm/yyyy) 
·Ethnicity:   white        1      black Caribbean         2          black African         3 
   Indian/Pakistani/Bangladeshi        4        mixed background         5 
   other(please specify)                 not known         9  
          / /
iii) CLINICAL DETAILS     
·Clinical presentation:                bacteraemia                 septic arthritis        
  toxic shock-like syndrome              cellulitis                     pneumonia          
necrotising fasciitis                                         meningitis             puerperal sepsis          
erysipelas            other (please specify) 
 ·Degree of severity:     hypotensive shock              renal impairment     
    DIC              liver abnormality          respiratory distress                
  erythematous rash               soft-tissue necrosis                                    
  none of these                  not known         
·Clinical management:     
    admitted to I.T.U.? YES/NO/not known (please delete)    If YES,  no. days 
    spent in ITU (of  the 7 days following GAS isolation)             days 
    surgical intervention?   YES/NO/not known (please delete)    (please specify  
procedures)  
·Outcome (at one week after GAS isolation)  not known          9   alive        0 
     died – GAS infection was main/underlying cause of death          1 
             – GAS infection contributed to death (not main cause)        2 
             – GAS did not contribute to death        3    – cause unknown        4 
iv) EPIDEMIOLOGICAL INFORMATION 
·Risk factors:   steroid use             diabetes        injecting drug user 
      varicella                      non-steroidal anti-inflammatory drugs        
alcoholism            malignancy            skin lesion/wound         If YES:     
     trauma        1     insect bite        2              surgery         3  (please specify) 
 
    recent childbirth (last  4 weeks)            If YES: date:  
            vaginal deliver/caesarean section (please delete) 
    other risk factor/s including immunosupression or previous GAS  
      disease (within last 14 days) (please give details) 
 
 
   no identified risk factors               information not known       
·Other epidemiological information                                           
Occupation of patient:                                                                
Recent overseas travel (last 2 weeks)?  YES/NO/not known (please delete)  
  If YES, which country/ies? 
      
   Was the patient admitted from an institution? YES/NO/not known 
      If YES, what  type?  
   Was this infection hospital acquired? YES/NO/not known  (please delete)  
      Was this case related/contact of other case(s) of GAS disease?       
     YES/NO/not known (please delete)   If YES, please provide details -    
       relationship to this case: 
       date of onset/specimen of related case:  
       clinical presentation of related case: 
 
 
--- thank you for completing this questionnaire ---
        / /
/ /
/ /
/ /
ADDITIONAL INFORMATION  
Please provide any additional information of interest 
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E N H A N C E D  S U R V E I L L A N C E  O F   
S E V E R E  G R O U P  A  
S T R E P T O C O C C A L  I N F E C T I O N
 
strep-EURO - is a three year European Commission Framework Five programme for severe group A streptococcal (GAS) disease in Europe, 
launched on 1st September 2002. Its aim is to enhance our understanding of the epidemiology of GAS invasive disease in Europe. In fulfilment 
of the aims of the programme, nine countries are undertaking enhanced surveillance and isolate collection for all cases of severe GAS disease 
occurring between 1st January 2003 and 31st December 2004.   It is hoped that this will provide valuable data to inform future treatment and 
vaccine strategies for severe GAS disease. The participating countries are Sweden, Germany, Finland, United Kingdom, Italy, Greece, 
Denmark, Czech Republic, Cyprus and Romania. 
Public Health Laboratory Service. Enhanced surveillance of invasive group A streptococcal infections. Commun Dis Report CDR Wkly [serial 
online] 2002 [cited 19 December  2002]; 12 (51).  
 
Guidance on the completion of the form - please complete one reporting form for each case diagnosed in your laboratory between 
1st January 2003 and 31st December 2004, meeting the following case definition of severe group A streptococcal disease: 
 
Isolation of a group A streptococcus (Streptococcus pyogenes) from a site that is normally sterile: blood; cerebrospinal 
fluid; joint aspirates; pericardial/peritoneal/pleural fluids; deep tissue or abscess at operation or necropsy; bone.  
 
Please complete as much of this form as possible and return in the pre-paid envelope to: Dr A Efstratiou, Health Protection Agency, 
Respiratory and Systemic Infection Laboratory, Specialist and Reference Microbiology Services Division, 61 Colindale Avenue, 
London NW9 5HT.  All information supplied will be treated as confidential; under no circumstances will individual case details be passed on to 
a third party. The following definitions will help with completion of the sections overleaf. 
If you have any queries on this questionnaire or surveillance programme, please contact  
Section i) & ii) 
SOUNDEX – coding system for anonymisation of patient’s surname (e.g. L265).  Please supply if known. 
date of hospital admission – please give the date the patient was admitted to hospital during this hospital stay 
Other relevant pathogens associated with this illness – please state if any other organisms thought to be clinically significant to this
episode have been isolated from this/these site/s.  
 
Section iii) 
Clinical presentation 
Toxic shock syndrome – please indicate for confirmed or possible cases, defined as ‘Isolation of a group A streptococcus with
hypotension (BP90mm Hg) and two or more of the following: renal impairment, coagulopathy, liver abnormalities, acute respiratory
distress syndrome, extensive tissue necrosis, erythematous rash’. 
Degree of severity  - please indicate those that apply   
Hypotensive shock – blood pressure 90mm Hg 
Renal impairment – two-fold elevation of age-adjusted creatinine level (or higher) 
DIC (disseminated intravascular coagulation) - thrombocytes <109/litre 
Liver abnormality – raised sGOT, sGPT or two-fold elevation of bilirubin levels (or higher) 
Soft tissue necrosis - fasciitis, myositis or gangrene 
Clinical management  
Admitted to ITU – please indicate if the patient has as a result of this infection been admitted to an intensive care/therapy unit and how
many days were spent in ITU within the first week following GAS isolation  
Surgical intervention – please describe, using OPCS-4 codes for surgical procedure/s if available  
Outcome – at one week after initial GAS isolation 
 
Section iv) 
Risk factors  - please tick any that apply, noting any other possible risk factors, including disease or treatment-related immunosuppression
and previous GAS disease (within the 14 days prior to this isolation) in the ‘other risk factors’ box.  Please describe any surgical
procedure/s, giving OPCS-4 codes if available.   
Other epidemiological information 
Occupation – please state type if occupational exposure is thought to have possibly occurred 
Admitted from an institution – please indicate if the patient was admitted to hospital directly from another closed institution and state
what type and which country if outside UK (e.g. transfer from Greek hospital, nursing home, prison) 
Hospital acquired infection – defined as infection occurring 48 hours after hospital admission (including time in originating hospital in
the case of transfer) 
              European Commission DG RTD QLK2.CT.2002.01398 
Dr Androulla Efstratiou 020 8200 4400 ext.4270/4288.   
Thank you for your assistance in this surveillance programme 
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10.2. European Standard Population 
 
Age group (years) European Standard Population 
0 1,600 
1-4 6,400 
5-9 7,000 
10-14 7,000 
15-19 7,000 
20-24 7,000 
25-29 7,000 
30-34 7,000 
35-39 7,000 
40-44 7,000 
45-49 7,000 
50-54 7,000 
55-59 6,000 
60-64 5,000 
65-69 4,000 
70-74 3,000 
75-79 2,000 
80-84 1,000 
85+ 1,000 
Total 100,000 
